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Compounding has remained 
an integral part of hospital 
pharmacy practice since the lack of 
appropriate manufactured paediatric 
formulations is a worldwide 
problem. This study investigated the 
pharmaceutical quality of different 
extemporaneous oral formulations 
for paediatric use from preterm 
newborns to children. The question 
to be answered is whether nifedipine 
preparations dispensed as hard 
gelatin capsules, oral powders or as 
unit-dose or multi-dose suspensions 
are sufficiently uniform and stable?
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ABSTRACT:  
 
Despite efforts to improve the availability of commercial drug products for children, there is still a 
widespread need for compounded preparations. Age-appropriate dosage forms formulated at 
different strengths containing harmless excipients are routinely needed. Therefore, hospital 
pharmacies still compound a wide range of preparations although there are no appropriate and 
comprehensive published standards. 
The present study examined the chemical and physical stabilities and content uniformities of one 
compounded, nifedipine in 1 mg oral dosage forms by using reproducible and validated stability-
indicating high performance liquid chromatography (HPLC) methods.  Individually weighed oral 
powders, hard gelatin capsules and unit-dose or multi-dose suspensions were compounded either by 
using a crushed commercial tablet or from nifedipine drug powder.  
The results indicate that both solid and liquid oral dosage forms may provide suitable solutions to 
treat paediatric patients of different ages. The total mass of the nifedipine oral powder had to be 300 
mg or more in order to ensure accurate dosage. When the mass was 100 mg or 50 mg, the nifedipine 
amount was less than 80% of the targeted amount. Most of the missing amount was located on the 
emptied powder papers. Nifedipine capsules, sizes 1–4 (0.21–0.50 ml), whose contents were emptied 
prior to use, do represent a good alternative to oral powders when comparing the recovery. 
Nifedipine 1 mg/ml unit-dose suspension in hypromellose 1% was chosen as the formulation for 
administration via nasogastric feeding tubes. Oral powders were chemically stable for the studied 
period of 12 months and unit-dose suspensions were chemically, physically and microbiologically 
stable for four weeks, at room temperature or in the refrigerator. Due to the light sensitivity of 
nifedipine, it required protection from light during handling and storage. When exposed to artificial 
daylight, 20–30% photodegradation occurred within three hours. The content uniformities of the 
nifedipine unit-dose suspensions, powders and capsules met the requirements of the European 
Pharmacopoeia. Vigorous agitation, i.e. inverting the bottle 10-15 times instead of three times, was 
critical for ensuring the content uniformity of nifedipine 1 mg/ml multi-dose suspensions 
compounded with extemporaneous vehicles. In contrast, nifedipine 1 mg/ml multidose suspensions 
passed the test if the bottle was inverted only three times when more sophisticated commercial 
suspension vehicles were used.  
In conclusion, compounded nifedipine oral powders and unit-dose suspensions were stable and 
uniform throughout the study periods when protected from light. Emptying of capsules represents an 
alternative to oral powders. The agitation of suspension vehicle is important to ensure the quality of 
oral multi-dose suspensions. The individual needs of each child’s in nifedipine medication can be 
satisfied with these age-appropriate dosage forms. 
 
National Library of Medicine Classification: QV 754, QV 779, QV 786, WX 179 
Medical Subject Headings: Pharmacy Service, Hospital; Pediatrics; Pharmaceutical Preparations; Drug 
Compounding; Dosage Forms; Capsules; Powders; Suspensions; Nifedipine; Drug Stability; Chromatography, 
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TIIVISTELMÄ:  
 
Lasten lääkehoidon kehityksestä huolimatta kaupallinen lääkevalikoima ei kata kaikkia 
lapsipotilaiden lääkitystarpeita. Suurin osa valmisteista on suunniteltu ja tutkittu ainoastaan 
aikuisilla eikä niitä voida käyttää sellaisenaan lapsille, joille tarvittaisiin useita vahvuuksia, 
sopivia lääkemuotoja ja turvallisia, haitattomia apuaineita. Siksi sairaala-apteekeissa 
valmistetaan edelleen runsaasti ex tempore –lääkevalmisteita lapsille. Ne ovat 
myyntiluvattomia tuotteita, joita on tutkittu melko vähän. 
Tässä työssä tutkittiin sairaala-apteekissa valmistettujen suun kautta annettavien 
nifedipiinivalmisteiden kemiallista ja fysikaalista säilyvyyttä ja annosvaihtelua. Analytiikassa 
käytettiin muun muassa korkean erotuskyvyn nestekromatografiaa (HPLC). Yksitellen 
punnitut jauheet, kovat liivatekapselit ja yksittäisannoksiksi tai pulloon pakatut suspensiot 
valmistettiin joko murskatuista tableteista tai nifedipiinipuhdasaineesta. 
Sekä kiinteitä että nestemäisiä lääkevalmisteita voidaan käyttää eri ikäisten lasten hoitoon. 
Tutkimuksessa havaittiin, että nifedipiinijauheiden massan on oltava vähintään 300 mg, jotta 
saadaan riittävän tarkkoja annoksia. Kun jauheiden massa oli 100 tai 50 mg, nifedipiinin 
saanto oli alle 80% tavoitepitoisuudesta. Lääkeainetta jäi eniten tyhjennettyihin 
annosjauhekuoriin. Tyhjennettävät kapselit, koot 1–4 (0,21–0,50 ml), ovat varteenotettava 
vaihtoehto jauheille, sillä nifedipiinin saanto pysyy riittävänä. Vastasyntyneiden 
nenämahaletkulääkintää varten kehitettiin yksittäispakatut nifedipiiniannossuspensiot, joissa 
apuaineena käytettiin 1% hypromelloosia. Jauheet säilyivät kemiallisesti muuttumattomina 
12 kuukauden tutkimuksen ajan ja yksittäispakatut suspensiot kemiallisesti, fysikaalisesti ja 
mikrobiologisesti neljä viikkoa sekä huoneenlämmössä että jääkaapissa. Valonarka 
nifedipiini on suojattava valolta käsittelyn ja säilytyksen aikana, sillä valolle altistettuna 20–
30% lääkeaineesta hajoaa kolmessa tunnissa. Yksittäisannoksiksi pakattujen suspensioiden, 
jauheiden ja kapseleiden annosvaihtelu täytti Euroopan farmakopean vaatimukset. 
Ravistelun määrällä on suuri merkitys moniannossupensioiden annosvaihtelulle. Kun 
käytettiin apteekissa valmistettua suspensiopohjaa, tarvittiin 10–15 kääntelyn huolellinen 
ravistelu, kun sen sijaan kaupallisiin, teollisesti kehitettyihin suspensiopohjiin valmistetut 
nifedipiinisuspensiot sekoittuivat hyvin jo vähällä, 3 kääntelyn ravistelulla.  
Tutkimuksen perusteella nifedipiinijauheet ja yksittäispakatut suspensiot säilyivät hyvin ja 
tasalaatuisina tutkimuksen ajan, kun ne suojattiin valolta. Tyhjennettävät kapselit ovat hyvä 
vaihtoehto suun kautta annettavaksi kiinteäksi lääkevalmisteeksi. Suspensiopohjan valinta 
vaikuttaa merkittävästi moniannossuspensioiden laatuun. Tutkituilla nifedipiinivalmisteilla 
on mahdollista täyttää lapsipotilaiden yksilölliset lääkitystarpeet. 
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   The latin word Infant means speechless.  
We have to speak on behalf of the speechless. 
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Definitions 
 
ADOLESCENT From 12 years to less than 18 years. 
CHILD   From 2 years to less than 12 years. 
COMPOUNDING The process undertaken by the individual pharmacist who 
creates a medicine from active drug substance and 
excipients or from an authorised dosage form and excipients 
when no suitable dosage form is commercially or locally 
available (Ernest et al. 2012). Also known as extemporaneous 
dispensing or preparation.  
EXTEMPORANEOUS 
PREPARATION 
A product, which is dispensed immediately after 
preparation and not kept in stock (Pharmaceutical 
Inspection Convention, 2008). 
INFANT From 1 month to less than 12 months. 
MANIPULATION Modification of marketed dosage form at time of 
administration, eg. segmenting or splitting tablet or mixing 
with food (Ernest et al. 2012). 
NEWBORN (NEONATE) From birth to 28 days of age. 
OFF-LABEL USE OF 
MEDICINES 
All uses of a marketed drug not detailed in the Summary of 
product characteristics including therapeutic indication, use 
in age-subsets, appropriate strength (dosage), 
pharmaceutical form and route of administration (Neubert 
et al., 2008). 
PRETERM NEWBORN 
(PREMATURE) 
Born before 37 weeks of gestation. 
RECONSTITUTION Manipulation to enable the use or application of a medicinal 
product with a marketing authorization in accordance with 
the instructions given in the summary of product 
characteristics or the patient information leaflet (Council of 
Europe Resolution CM/ResAP(2011)1). 
  
  
SPECIALS Extemporaneous preparations that are made in larger 
volumes by licensed manufacturers. 
STABILITY The extent to which a preparation retains, within specified 
limits, and throughout its period of storage and use, the 
same properties and characteristics that is possessed at the 
time of compounding (The United States Pharmacopeial 
Convention, 2008). 
TODDLER From 1 year to less than 2 years of age. 
UNLICENCED USE OF 
MEDICINES 
All uses of a drug, which have not received a European 
marketing authorisation as medicinal for human use in 
either adults or children (Neubert et al., 2008). 
The categories: medicines compounded extemporaneously, 
modifications to licensed product, particular formulation 
manufactured under a ‘specials’ licence ‘, unlicensed drug 
made by a licensed manufacturer, a chemical used as a 
medicine, drugs used prior to granting of a licence or under 
special manufacturing licence, and imported drugs which 
are licensed in the country of origin (Turner et al., 1998). 
XX 
 
 
 1 Introduction 
Compounding has remained an integral part of pharmacy practice. Extemporaneous 
compounding in hospitals and community pharmacies is important since it allows the 
provision of age-appropriate dosage forms when suitable authorised medicines are not 
available (Giam and McLachlan, 2008; Nunn, Aindow and Woods, 2012). The 
compounding of customised medicines is needed in particular situations in which the 
proprietary medicines available do not meet the specific needs of the patients: need for 
particular strengths, alternative dosage forms, ingredients or organoleptic characteristics 
(Carvalho, Taylor and Tuleu, 2012).  
The lack of appropriate manufactured paediatric formulations is a worldwide problem 
(Giacoia, Taylor-Zapata and Mattison, 2007a). Since many drugs are not licensed for use in 
paediatric populations, the manufacturer does not usually produce age-appropriate dosage 
forms for the market (Pai and Nahata, 2001). There are also situations where the medicines 
are not available from commercial suppliers: shortages of medicines, discontinued 
medicines, special combinations or orphan medicines (Carvalho, Taylor and Tuleu, 2012). A 
positive trend in the approval of safe and efficacious medicines for children seems to be in 
progress in Europe (Ceci et al., 2006). The European paediatric regulation (Regulation (EC) 
No 1901/2006) had a positive impact on achieving this goal.  
This dissertation, where the extemporaneous compounding of oral paediatric 
formulations is examined, is in a field where rather limited amounts of research have been 
published. Without specific technical information, pharmacists are often forced to rely on 
their professional skills and general knowledge of pharmaceutical compounding science. 
This study is restricted mainly to extemporaneous oral formulations for use in preterm and 
term newborns, infants and toddlers. In these age groups, the range of doses and dosage 
forms used may be wide, because of the developmental changes that occur during the first 
years of life (Tuleu, 2007). 
Nifedipine is one of the drugs which may need to be administered for all these age 
groups as an extemporaneous preparation because in Finland commercial nifedipine is 
available as either tablets or extended-release tablets (Pai and Nahata, 2001; Standing and 
Tuleu, 2005; Sahney, 2006). In Kuopio University Hospital, over 5600 nifedipine powders 
were compounded in 1994 and although less in 2012, still over 1100 oral unit-dose syringes 
were prepared. Extended-release nifedipine is one of the most commonly used oral calcium 
channel antagonists (CCA) in the treatment of chronic paediatric hypertension (Moncica et 
al., 1995; Sadowski and Falkner 1996; Sinaiko, 1996, Silverstein et al., 1999; Sahney, 2006; 
Seikaly, 2007; Meyers and Siu, 2011). Nifedipine is also one of the oldest agents in therapy 
of paediatric pulmonary arterial hypertension although today it is limited to selected 
patients who need to undergo a positive acute vasodilator challenge (Hawkins and Tulloh, 
2009; Ivy, 2012). Nifedipine has also been indicated in bronchopulmonary dysplasia (BPD), 
a result of lung injury mostly encountered in low birth weight preterm infants requiring 
mechanical ventilation and supplemental oxygen (Kochanek, 1985; Brownlee, Beekman and 
Rosenthal, 1988; Johnson et al., 1991; Ali et al., 2013; Zysman-Colman et al., 2013).  
The aim of this study was first to formulate, then to characterize in vitro and finally to 
compare different extemporaneous oral formulations of nifedipine intended for paediatric 
use from preterm newborns to children. The stability and uniformity of dosage units were a 
focus of special investigation. In this respect, nifedipine is an ideal model drug due to its 
undesirable physicochemical properties, such as insolubility in water and sensitivity to 
light. 
 2 
2 Review of the Literature 
2.1 AUTHORIZED MEDICINES  
Of all the active substances that were authorized and issued with a Marketing 
Authorisation (MA) by the European Agency for the Evaluation of Medicinal Products in 
the period October 1995 to September 2005, only 33% were licensed for paediatric use, 23% 
for use in infants and only 9% were available for newborns (Ceci et al., 2006). During the 
last 14 years, the FDA has updated the labeling of 434 drugs for which studies have been 
completed in children, but only one is a product intended for premature infants (Davis, 
Connor and Wood, 2012). Since the introduction of antenatal corticosteroids and surfactant 
15 to 20 years ago, no new medications appeared that would have substantially improved 
the outcome for preterm infants. 
The paediatric market is comparatively small and segmented by age groups, 
necessitating different formulations and dosing for each age group (Leff and Roberts, 1987; 
Primovic, 1993; Nahata, 1999a; Steinbrook, 2002; Glass and Haywood, 2006; Ernest et al., 
2007; Giacoia, Taylor-Zapata and Mattison, 2007b; Nahata and Allen, 2008). Drug testing is 
costly, time-consuming and could result in a poor return on investment. During recent 
years, there has been a trend in the pharmaceutical industry to decrease the variety and 
number of dosage forms being marketed (Allen, 2003). Therapeutic advances (e.g. 
modified-release forms) are rarely available for children. In the future, the paediatric drug 
formulation and adult formulations should be developed in tandem (Salunke et al., 2011).  
The Regulation issued by the European Parliament and of the Council on Medicinal 
Product for Paediatric Use came into force in January 2007, nearly ten years later than the 
corresponding mandatory regulation in the USA. It obliges the pharmaceutical industry to 
undertake clinical trials in the paediatric population (Regulation (EC) No 1901/2006 of the 
European Parliament and of the Council, 2006; Breitkreutz, 2008). There are several goals of 
this regulation: to facilitate the development and accessibility of medicinal products for use 
in children, to ascertain that medicinal products used to treat the paediatric population are 
subject to ethical research of high quality, to ensure that medicinal products are 
appropriately authorised for use in the children, to improve the information available on 
the use of medicinal products in the various paediatric populations, to achieve these 
objectives without subjecting children to unnecessary clinical trials and to prevent any 
delay in the authorisation of medicinal products for other age groups.  
Four key measures were introduced by the new European Union (EU) legislation: 
installing an expert committee on paediatric medicines (Paediatric Committee, PDCO) at 
the EMA, requesting a Paediatric Investigation Plan (PIP) at an early stage of clinical 
development for all new chemical entities, granting a Supplementary protection certificate 
and market exclusivity for a new drug which have been developed with adherence to the 
agreed PIP, and granting a Paediatric Use Marketing Authorisation (PUMA) for drug 
substances with expired patent protection (Regulation (EC) No 1901/2006 of the European 
Parliament and of the Council, 2006; Breitkreutz, 2008). In addition, EMA and PDCO have 
drawn up a priority list of off-patent medicinal products for which studies are required 
(European Medicines Agency EMA/98717/2012, 2012). As a result, various collaborative 
project groups have been established in the EU in recent years (Breitkreutz, 2008; Finney, 
2011). Both European Medicines Agency and World Health Organization have published 
guidance on pharmaceutical development of paediatric medicines (European Medicines 
Agency, 2006; European Medicines Agency EMA/CHMP/QWP/805880/2012 Rev. 2, 2013; World 
Health Organization, 2012). 
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Over a period of five years, up to the end of 2011, the Paediatric Committee had 
evaluated PIPs for 683 medicines, of which 70% were in adherence to a PIP (European 
Medicines Agency EMA/428172/2012, 2012). The plans led to new paediatric indications in 24 
medicines and to new pharmaceutical forms appropriate for children in 7 medicines, which 
is not as many as it was expected (Lindell-Osuagwu et al., submitted). Ten new medicinal 
products out of 113 new active substances were centrally authorized and received a 
paediatric indication. 
2.2 OFF-LABEL AND UNLICENSED MEDICINES  
Off-label and unlicensed use of drugs in paediatric drug therapy occurs in all countries and 
specialty areas of practice (Conroy and McIntyre, 2005; Giam and McLachlan, 2008; 
Kimland and Odlind, 2012; Mason, Pirmohamed and Nunn 2012). Many medicines licensed 
for use in adults are not officially licensed for infants, even though their use may be 
considered as the current standard of care.  
Prescription, dispensing and administration of unlicensed and off-label medicines are 
permitted according to the legislation in most countries, including EU countries; this 
procedure is not forbidden in Finnish legislation (Turner, Nunn and Choonara, 1997; Giam 
and McLachlan, 2008; Ministry of Social Affairs and Health, 2010). However, in some 
countries e.g. India, unlicensed and off-label prescribing is considered illegal (Mudur, 2004; 
Conroy and McIntyre, 2005). 
2.2.1 Use 
The off-label and unlicensed use of medicines in paediatrics is common in many countries. 
In hospital and neonatal care studies, the proportion of off-label use has ranged from 10% 
up to 65% of all prescriptions (Kimland and Odlind, 2012). In outpatient care, the 
proportion of off-label drug prescriptions has varied between 11% and 31% (McIntyre et al., 
2000; Olsson et al., 2011; Kimland and Odlind, 2012). The lack of common definitions for 
off-label and unlicensed use of medicines complicates comparison between different 
countries (Neubert et al., 2008). 
The unlicensed drug use in hospital wards accounted for 4.6% of prescriptions in 
Sweden, 6.9% in United Kingdom but as high as 48% in the Netherlands (Turner et al. 1998; 
‘t Jong et al., 2001; Kimland et al., 2012). National differences are also apparent in the 
unlicensed drug use in outpatient care i.e. 0.3% in an English study but 16.6% of the total 
prescriptions in a Dutch study and if one considered the age group 0–1 year then the 
percentage rose to 34.7% (McIntyre et al., 2000; Schirm, Tobi and de Jong-van den Berg, 
2003).  
In a Finnish study conducted in 2001 in a neonatal intensive care unit (NICU), general 
paediatric ward and paediatric surgical ward in Kuopio University Hospital, it was found 
that of all prescriptions (n=629), 51% were for licensed drugs, 36% for off-label use and 13% 
for unlicensed drugs (Lindell-Osuagwu et al., 2009). The age groups most commonly 
receiving unlicensed drugs were neonates, infants and toddlers. However, in 2011 
prescriptions for unlicensed medicines compounded by the hospital pharmacy were less 
common than in 2001 (Lindell-Osuagwu et al., submitted). The overall proportion of 
prescriptions for unlicensed drugs (13%) was similar to that described in other studies (11–
12%) in paediatric intensive care units in Australia and Italy (O’Donnell, Stone and Morley, 
2002; Dell’Aera et al., 2007; Lindell-Osuagwu et al., 2009). The majority, from 67% to 80% of 
European and Australian infants, 93% of extremely low birth weigh infants in Australia 
and even all patients in Kuopio University Hospital need to receive at least one unlicensed 
or off-label medicine during their stay in the NICU (Conroy et al., 2000; O’Donnell, Stone 
and Morley, 2002; Lindell-Osuagwu et al., submitted).  
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In the European study it was noted that the majority, 60%, of those most important 
extemporaneous products were marketed as suitable licensed paediatric formulations in 
other European countries, North America or Australia (Brion, Nunn and Rieutord, 2003). 
Thus, regulatory authorities need to cooperate to ensure licensing approval in all European 
countries and to enable free movement of licensed medicines between European countries. 
Today special permission for compassionate use is needed from the Finnish Medicines 
Agency. Cost and transporting time may also prevent the willingness to import. 
2.2.2 Risks 
Knowledge of drug administration in children has lagged behind that of adults (Sinha and 
Cranswick, 2007). The skill and judgement of physicians and pharmacists are critical in 
ensuring that the patient receives the appropriate drug, the best dosage form and an 
optimal dosing regimen. In the absence of specific clinical trial-based data in children, 
clinicians are forced to rely on experience from adult patients, although children have 
different pharmacokinetics to adults and their response to many medicines can be 
unpredictable (Nahata, 1992; Pagliaro, 2002; Conroy and McIntyre, 2005; Costello, 2007; 
Williams, 2013). The decision to use a drug in neonates is often based on a number of 
factors such as the clinical experience of the prescribing physician, an expert opinion, 
studies in older children, or a pilot study in newborns (Sinha and Cranswick, 2007; Davis, 
Connor and Wood, 2012). 
 In 2010, out of an estimated 134.2 million livebirths worldwide, 11.1% were born 
preterm, ranging from about 5% in several European countries up to 18% in some African 
countries (Blencowe et al., 2012). Unlicensed and off-label medicine use is more likely to 
occur in newborn infants, who may be predisposed to suffer adverse drug reactions (ADRs) 
due to their physiological immaturity (Zenk, 1994; Conroy and McIntyre, 2005; Costello, 
2007).  
The lack of suitably adapted medicines and calculated individualized doses for children 
may increase the risk of ADRs and/or ineffective treatment: either under- or over-dosing 
(Costello, 2007; Pagliaro, 2002). According to a large review of 102 studies, the use of 
multiple drugs seems to be an important predictor of the appearance of ADRs in children 
(Smyth et al., 2012). Anti-infectives and anti-epileptics were the most frequently reported 
therapeutic classes associated with ADRs in hospitalized children and anti-infectives and 
non-steroidal anti-inflammatory drugs were frequently associated with ADRs in paediatric 
outpatients. Furthermore ADRs occurred in 3.9% of the licensed drug prescriptions and in 
6% of the unlicensed or off-label precriptions in paediatric inpatients (Turner et al., 1999). 
Evaluation of the studies confirm the higher risk of ADRs when prescribing is unlicensed or 
off-label and also indicate that these ADRs can be serious but there is still lack of clarity and 
this is an area that needs further research (Conroy and McIntyre, 2005; Mason, Pirmohamed 
and Nunn, 2012).  
When a drug is not approved for use in infants and children, it is usually not available in 
an appropriate dosage form, formulation, size or concentration for the paediatric 
population. Children are often unable to swallow capsules or tablets due to anatomy of 
their buccal cavity, and consequently some deaths has been reported associated with 
aspiration of solid dosage forms (Reilly and Walter, 1992; Tuleu, 2007; Ernest et al., 2007; 
Giacoia, Taylor-Zapata and Mattison, 2007a). Many pharmaceutical preparations contain 
ingredients that have been reported to cause ADRs for paediatric patients (Leff and 
Roberts, 1987; Ernest et al., 2007). The range of doses needed may be wide because there is 
such a wide variation in body mass and developmental biological and pharmacological 
features (Nahata, 1991; Wong, 2007; Ernest, et al., 2007).  
Ampoules normally contain adult-sized doses and even ampoules or vials intended for 
children may contain much more than required for neonates (Choonara and Nunn, 2006). 
In addition, drug products intended for adults are not often available in a concentration 
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low enough to permit accurate and precise dispensing of small doses (Nahata, 1999a; 
Nahata, 1999b). At the point of administration 10% of doses required some kind of 
manipulation or measurement of a small volume, e.g. under 0.2 ml volume (Nunn et al., 
2013). Trying to measure less than 0.1 ml or a dilution to permit a larger volume to be 
dispensed was needed in 25% of the manipulated drugs. Errors may occur in measuring 
doses under 0.1 ml and measurement errors with potent drugs like morphine and digoxin 
have been reported as sources of intoxication and deaths in paediatric patients (Nahata, 
1999a; Nahata, 1999b; Wong, 2007). Dilutions of 1:10 or 1:100 are often required to 
accurately measure the required doses (Zenk, 1994). 
The total blood volume of a 500 g preterm infant is 40 ml (Ernest et al., 2007). A 1 kg 
neonate may only receive a total of 150 ml of fluids each day, and this much include all 
nutritional requirements as well as therapy (European Medicines Agency, 2006). Seriously ill 
neonates are often fluid restricted, limiting the volume of medications that can be 
administered (Glass and Haywood, 2006). The delay in administration of intravenous drugs 
in paediatric patients may be as long as several hours (Roberts, 1994). In premature infants, 
intravenous flow rates of <10 ml/hour, even as low as 3 ml/hour, can require about 6 to 18 
hours for drugs to be completely infused into the patient.  
Concentrated and high-osmolality (>400-500mOsm/kg) oral dosage forms may be 
associated with irritating effects on the gastrointestinal tract, resulting in nausea, vomiting, 
diarrhoea or necrotizing enterocolitis (NEC) mainly in preterm newborns (Zenk and 
Huxtable, 1978; White and Harkavy, 1982; Leff and Roberts 1987; Pagliaro, 2002). NEC is 
characterized by damage to the intestinal mucosa, which can progress to necrosis, even 
intestinal perforation and is associated with high rates of morbidity and mortality (Willis et 
al., 1977; Polo et al., 2007). Prematurity is the most important risk factor associated with 
NEC and the frequency of NEC is 1–3/1000 live births (Polo et al., 2007). 
The osmolality of the human milk is about 300 mOsm/kg (Tomarelli, 1976; Zenk and 
Huxtable, 1978). In several studies it has been observed that most of the oral liquids used in 
NICU and intensive care nursery were hyperosmolalic: in four published studies 100%, 
96%, 75% and 96% of the analysed oral products were over 1000 mOsm/kg, respectively 
(White and Harkavy, 1982; Ernst et al. 1983; Mutz and Obladen, 1985; Polo et al., 2007). In 
many products, the high osmolality is not due to the active ingredient but to ‚inactive‛ 
excipients such as propylene glycol or sorbitol (Ernst et al., 1983; Mutz and Obladen, 1985). 
2.3 COMPOUNDED PREPARATIONS  
Compounded formulations can be considered as one subgroup of unlicensed drugs and it 
includes modifications to commercially manufactured products such as the preparation of a 
suspension or powders from tablets, or the preparation of a product from the individual 
raw materials (Giam and McLachan, 2008). The type of reconstitution where medicinal 
products are made ready for immediate administration (e.g. dissolution of a powder 
according to the appropriate instructions) is normally not considered as compounding 
(Pharmaceutical Inspection Convention, 2008). In addition, dividing or grinding solid 
dosage forms, dissolving tablets in water due to the inability of the patient to swallow the 
solid dosage form or administering fractions of a liquid, which nurses regularly do on the 
wards and at the bedside, is not extemporaneous preparation (Giam and McLachan, 2008; 
Nissen, Haywood and Steadman, 2009).  
The basis for compounding medicine can be traced to the societies of Ancient Egypt, 
Greece, Rome and especially the Arabian cultures, where advanced levels of medical 
knowledge were developed (Marriot et al., 2010). It has been estimated that a broad 
knowledge of compounding was still essential for 80% of the prescriptions dispensed as 
late as in the 1920’s (Sundberg, 1997; Allen, 2006; Trissel, 2009). The majority of 
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prescriptions were compounded by a pharmacist according to the order of a physician for 
each individual patient. 
Giam and McLachlan (2008) reviewed 20 published studies to identify the relative extent 
of extemporaneous product use in the paediatric population. In the general medical and 
surgical wards, the frequency of extemporaneous or ‘special’ product use was reported to 
range from 2% to 26%. In the neonatal wards, extemporaneously prepared products or 
‘specials’ were dispensed in 5–11% of all prescriptions. In the United Kingdom (UK), it was 
reported that almost half of the 45 (9.9%) extemporaneous products that were being 
prescribed had been compounded by the pharmacy with the rest being prepared by 
‘specials’ manufacturers. The use of extemporaneous products and ‘specials’ was similar 
across all paediatric ages and conditions.  
Extemporaneous products have been compounded most frequently in countries such as 
the Netherlands, where pharmacy preparation services are widely available and 
approximately 5% of the total prescription numbers are compounded (Schirm, Tobi and de 
Jong-van den Berg, 2003; Giam and McLachlan, 2008). However, the produced volume in 
the Netherlands has fallen dramatically due to the demands imposed by increased quality 
standards (Le Brun, 2011).  
2.3.2 Dosage forms 
Methods of extemporaneous preparation vary in different European countries (Brion, Nunn 
and Rieutord, 2003). Liquids are predominantly (> 60% of doses) compounded in Denmark, 
England, Ireland, Norway and Sweden, capsules in Belgium, Croatia, France and 
Switzerland and powders in Finland, Italy and Scotland. One common practice in 
Germany, Spain and Slovenia involves the preparation of a less well-defined combination 
of liquids, powders and capsules. In the Netherlands, extemporaneous preparation often 
means reformulating a solid dosage form into a liquid dosage form for infants, or 
conversion of tablets into capsules with an appropriate dose for children (Le Brun, 2011). 
Chloral hydrate, midazolam and caffeine oral liquids, and spironolactone, captopril, 
phenobarbital, hydrocortisone and ranitidine oral capsules are compounded in many 
hospitals throughout Europe (Brion, Nunn and Rieutord, 2003).  
The types of compounded dosage forms have varied from time to time. In the late 1960s, 
mixtures and ointments were the most common extemporaneous preparations encountered 
in Sweden (Kettis Lindblad, 1996). In the years 1987–1989, dermatological preparations 
formed almost half of the total number of extemporaneous preparations, and mixtures, 
dental solutions, eye drops and capsules were the next most common in Sweden (Kettis 
Lindblad, 1996). On the other hand, in fifty English hospitals, a total of 256 different oral 
liquid formulations of 123 drugs were being prepared in the early 1980s (Purkiss and 
Kayes, 1981). 
The American Society of Hospital Pharmacy conducted a survey in 1989 and found that 
oral rifampicin, spironolactone and caffeine were the most frequent extemporaneously 
compounded formulations for paediatric patients in USA (Crawford and Dombrowski, 
2.3.1 Frequency 
In Sweden the proportion of prescriptions that require compounding decreased from 22% 
in 1956 to some 2.5% in 1986 (Kettis Lindblad, 1996). During the period 1987–1989 in 
relation to the total sales of drugs in Sweden, the proportion of extemporaneous 
preparations was about 1.5%; they were required most commonly for children. In 
Australia about 60% of the Victorian community pharmacies dispensed 1–5 
extemporaneous prescriptions per week in 1998, i.e. for 75% of the pharmacies 
extemporaneous prescriptions made up <1% of total prescriptions (Pappas, 1999). Such a 
small percentage is not universal; in German community pharmacies about 25 million 
extemporaneous preparations are compounded every year (Zueck, 2008). 
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1991). In the years 1998–1999, the most commonly prepared extemporaneous dosage form 
in USA was still a liquid formulation and the oral, gastric and nasogastric administration 
routes were most usual (Pai and Nahata, 2001).  
In eight large hospitals in New Zealand in 2004, a total of about 250 extemporaneous 
products were compounded per month with suspensions being the most frequently 
compounded oral dosage form (Kairuz et al., 2007). The most common products were 
omeprazole suspension, phenobarbitone solution, midazolam solution, thyroxine 
suspension, ursodeoxycholic acid suspension and suspensions or solutions containing beta-
blockers. In Australia, reconstituted products, ointments and creams were estimated as 
being the most common extemporaneous products in 1990s (Pappas, 1999). Subsequently, 
most of the preparations made in Queensland, Australia, were suspensions, eye drops and 
solutions (Cook, Ling and Lee, 2007). According to a questionnaire, a total of 95 different 
extemporaneous formulations were prepared by 28 hospital pharmacies.  
2.3.3 Quality risks 
Despite many improvements in quality, extemporaneous preparation is still confronted by 
a range of challenging issues especially quality issues when compared to off-label use of 
registered products or unlicensed use of commercially manufactured products (Table 1) 
(Leff and Roberts, 1987; Giam and McLachlan, 2008; Allen, 2010b). The same drug may be 
compounded in liquid, capsule or powder form according to different standards and 
monographs across Europe or even within the same European country. These differences 
reflect the different traditions of extemporaneous preparation (Brion, Nunn and Rieutord, 
2003; Carvalho, Tuleu and Taylor, 2008). In addition, many different concentrations may be 
compounded for each dosage form (Brion, Nunn and Rieutord, 2003).  
In a British survey of extemporaneous captopril formulations, it was discovered that 22 
hospitals were using nine different liquid formulations of captopril while four hospitals 
crushed the tablets and dispersed the powder in water (Mulla et al., 2007). A Canadian 
study also found a wide variation in the types of captopril formulations used: four of the 14 
centres were dispensing solid tablets, two dispensed solid tablets or liquid formulations 
and eight made different kinds of extemporaneously prepared liquid formulations (Bhatt, 
Thomas and Mondal, 2011). A British clinical study of 18 healthy adult volunteers provided 
evidence that unlicensed manufactured captopril liquid formulations were not 
bioequivalent to the licensed tablet form or to each other, and this could cause problems in 
the clinic (Mulla et al., 2011).  
U.S. Food and Drug Administration (FDA) noted in its survey conducted in 2006, that 
there were problems with the quality of some compounded drugs (U.S. Food and Drug 
Administration, 2006). Potency ranged from 67.5% to 268.4% of the amount of drug 
declared on the product labelling, mainly in female hormone products and local anaesthetic 
products. From 1990 to 2005, the FDA had received reports of 240 serious illnesses, even 
deaths, associated with improperly compounded products. In the 2001 survey, the FDA 
stated that 34% of the 29 sampled products failed standard quality tests performed, mostly 
in potency testing (U.S. Food and Drug Administration, 2001). The wrong method of 
compounding was reported as a medication error on a total of 115 times (6% of all 
medication errors) during the period from 1999 to 2000 in United States (Cowley, Williams 
and Cousins, 2001). Chollet and Jozwiakowski (2012) found that 25% of thirty 
hydroxyprogesterone caproate injections prepared in compounding pharmacies failed to 
meet the potency requirements. 
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Table 1. Quality risks and areas of concern in extemporaneously compounded drug products. 
 
Quality risk Reference 
Adverse drug reactions due to preparation error or instability 
or incompatibility of ingredients 
Tuleu, 2007; Giam and 
McLachlan, 2008 
Alternative routes of administration for commercial products: 
e.g. oral liquids rectally, eye drops in the ear or injectable 
solution orally leading to irritability and altered kinetics of 
absorption and bioavailability 
Glass and Haywood 2006; 
Tuleu, 2007; Nunn, 2003 
 
Bioavailability, efficacy and safety studies may not be 
available. Compounded formulations may not be bioequivalent 
to the licenced products or to each other. 
Nahata, 1999c; Standing and 
Tuleu, 2005; Tuleu, 2007; 
Giam and McLachlan, 2008; 
Mulla et al., 2011; BMJ Group, 
2012 
Dilution of commercial formulations leading to dilution of co-
solvents thus causing the precipitation of the drug and to dilution 
of preservatives resulting in microbial contamination 
Nahata, 1999a; Nahata, 
1999b; Glass and Haywood, 
2006; Tuleu, 2007; Ghulam et 
al., 2007 
Inaccuracy of dosing: dose uniformity and reproducibility Standing and Tuleu, 2005; 
Tuleu, 2007; BMJ Group, 2012 
Incompatibilities: excipients, manipulated solid dosage forms, 
food or beverages 
Standing and Tuleu, 2005; 
Haywood and Glass, 2007; 
Tuleu, 2007; Giam and 
McLachlan, 2008; Nissen, 
Haywood and Steadman, 2009 
Manipulation of adult dosage form of the available tablet, 
capsule or injection: lack of pure drug substances, harmful 
excipients, high osmolality, altered pharmacokinetics, cutting, 
crushing or dissolving of tablets/capsules that should not be 
modified 
Nahata, 1999b; Pagliaro, 
2002; Standing and Tuleu, 
2005; Glass and Haywood, 
2006; Tuleu, 2007; Nissen, 
Haywood and Steadman, 2009 
Microbiological contamination of multidose preparations with 
insufficient preservation leading to potential risks, especially in 
the premature and newborn  
Ghulam et al., 2007 
Non-standard formulations: lack of published standards Brion, Nunn and Rieutord, 
2003; Tuleu, 2007; Giacoia, 
Taylor-Zapata and Mattison, 
2007b; Ghulam et al. 2007; 
Jackson and Lowey, 2010 
Preparation process: drug losses during the crushing and 
administration process, lack of information about validation and 
reproducibility 
Tuleu, 2007; Nissen, Haywood 
and Steadman, 2009; BMJ 
Group, 2012 
Skills of the pharmacist: variability in overall compounding 
practices and training 
Treadway, Craddock and Leff, 
2007 
Stability data: chemical, physical or microbiological stability not 
studied, short shelf-life 
Pai and Nahata, 2001; Brion, 
Nunn and Rieutord, 2003; 
Standing and Tuleu, 2005; 
Tuleu, 2007; Giam and 
McLachlan, 2008 
Strengths: several different strengths compounded 
extemporaneously, 10-fold difference in available strengths, 10-
fold dosing errors, strengths expressed per ml or per 5 ml 
Standing and Tuleu, 2005; 
Jackson and Lowey, 2010 
Taste of the drug or the preparation itself Giacoia, Taylor-Zapata and 
Mattison, 2007b 
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Errors of dose calculations, problems with decimal points, e.g. omission or addition of 
zeroes were frequent, causing tenfold medication errors. These were reported at a mean 
rate of 0.062 per 100 patient days in the Hospital for Sick Children in Toronto, Canada 
(Doherty and Mc Donnell, 2012). Incorrect preparation was an error source in four 
medication errors out of 129 errors that reached patients. Kato et al. (2009) reported a case 
where a three-year-old boy received compounded thioridazine instead of erythromycin 
from a pharmacy owing to their similar commercial names. In another case, a measurement 
error by the compounding pharmacy resulted in a fatal colchinine concentration that was 
eight times greater than the recognized standard level (McKeown et al., 2007). Seifert and 
Jacobitz (2002) described three compounding errors out of a total of 40 pharmacy 
prescription dispensing errors. Compounding errors in liquids and capsules resulted in 12-
fold overdosage; there was even a case of 500-fold overdosage. 
There is North-American research from the years 1998-1999 stating that there were 103 
drug formulations that had neither compounding nor stability information available 
compared to 76 extemporaneous formulations for which adequate stability data was 
available (Pai and Nahata, 2001). However, longer or better stability data had been 
requested 109 formulations, such as captopril, hydralazine, spironolactone, ursodiol and 
nifedipine. With respect to the liquid dosage forms reviewed in the literature, the stability 
was considered to be unfavourable for only 6 of the 83 dosage forms (Glass and Haywood, 
2006). In an unpublished UK survey, it was noted that 54% of 112 paediatric 
extemporaneous formulations displayed inadequate data about stability (Brion, Nunn and 
Rieutord, 2003). In Queensland, Australia stability data was available for 78% of 
preparations (Cook, Ling and Lee, 2007). 
There are other risk factors associated with extemporaneous products, for example low 
concentration of a non-dissolved active ingredient, high susceptibility towards microbial 
growth, longer periods of storage or use, poor working technique and provision to a large 
number of patients (Pharmaceutical Inspection Convention, 2008). Due to the general lack 
of standards and peer-reviewed research in this field, it is recommended that a product 
should be dispensed extemporaneously only when no product with a MA is available and 
if there are no alternatives (Brion, Nunn and Rieutord, 2003; Nunn, 2003; BMJ Group, 2012; 
Jackson and Lowey, 2010). 
2.3.4 Need for standards 
Currently, there are neither appropriate nor comprehensive published standards about the 
process of extemporaneous preparation; in fact not all pharmacies compound according to 
published formulations (Brion, Nunn and Rieutord, 2003; Hurtado and Moffett, 2007; Giam 
and McLachlan, 2008; Nunn, Aindow and Woods, 2012). Standardised and verified 
methods of compounding with suitable instructions should be required (Ernest et al., 2012). 
The variability in the method of preparation should be minimised and there should be 
adherence to a method of quality assurance. In order to ensure product quality, it has been 
recommended that there should be harmonization of extemporaneous formulations and 
quality control procedures and collected data should be published as standards and 
uniformly implemented in all countries (Brion, Nunn and Rieutord, 2003; Nunn, 2003; 
Ghulam et al., 2007; Giacoia, Taylor-Zapata and Mattison, 2007b; Giam and McLachlan, 
2008).  
The European Pharmacopoeia contains a monograph about Pharmaceutical 
preparations, which allows the supply of unlicensed products to meet the special needs of 
individual patients with a suitable level of risk assessment being undertaken when 
considering this kind of the preparation (European Directorate for the Quality of Medicines 
& Health Care, 2013). USP26/NF21 Chapter <795> Pharmacy Compounding – Non-sterile 
preparations gives instructions including compounding process, stability, ingredients and 
quality control (Allen, 2011a; Allen, 2011b). The Australian government has also reviewed 
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the need for regulation of extemporaneous compounding in Australia (Australian 
government, 2005 and 2008; National coordinating committee on therapeutic goods 
(NCCTG), 2008). The relevant pharmacopoeial formularies are British Pharmacopoeia (BP), 
United States Pharmacopeia (USP), Australian Pharmacopoeia Formulae (APF) and 
Martindale (Allen, 2003; Glass and Haywood, 2006). In addition, many European states 
maintain complementary national pharmacopoeias, which may include some formulation 
or performance standards for compounded preparations.  
The general quality instructions of the extemporaneous preparation in addition to 
national administrative regulations are presented in GMP, PIC/S GPP, other PIC/S 
guidance, ICH-guidelines and other national quality guidelines (Sharp, 2000; 
Pharmaceutical Inspection Convention, 2008 and 2013; Finnish Medicines Agency, 2007 and 
2011; SHPA Manufacturing working party, 2010; European commission, 2012; ICH 
Guidelines, 2012). The Committee of Ministers published a resolution on quality and safety 
assurance requirements in order to avoid quality and safety gaps between medicinal 
products prepared in pharmacies and on an industry (Council of Europe Resolution 
CM/ResAP(2011)1). In this resolution, it is recommended that the GMP Guide be used as a 
reference for an appropriate quality system for high-risk preparations and the PIC/S GPP 
Guide be used for low-risk preparations. 
Suitable sources of stability-indicating information include formularies such as Allen’s 
compounded formulations, Nahata and Hipple’s Pediatric drug formulations, Trissel’s 
Stability of compounded formulations as well as peer-reviewed journals. In addition, some 
nations or individual hospitals like Calgary Health Region in Canada have created the 
formularies of their own to ensure that all practitioners use consistent formulas with 
confirmed stability information (Van Schijndel, 2002). The guidance contains usually the 
formula, conditions of storage and an estimate of shelf life based on chemical stability 
(Tuleu, 2007). However, there is often a lack of information about physical and 
microbiological stability and exact details of compounding. 
Nowadays clinical practise is not always accurately represented in the SmPC, 
particularly for agents which are no longer under patent protection (Sinha and Cranswick, 
2007). A reflection paper of EMA has encouraged manufacturers to provide relevant data of 
their products to practitioners, such as physicochemical data, excipients, pH, osmolality, 
dangers of manipulation, stabilities and compatibilities like compatible foods and drinks 
since this information would allow the pharmacist to dispense a satisfactory formulation 
(European Medicines Agency, 2006).  
2.4 UNIFORMITY AND STABILITY OF EXTEMPORANEOUS 
PREPARATIONS  
It has to be ensured that a formulation packaged in a specific container will remain within 
its physical, chemical and microbiological specifications during storage (Florence and 
Attwood, 2006). The main causes for limited stability are: 1) loss of drug (e.g. degradation), 
2) loss of vehicle (e.g. evaporation), 3) loss of uniformity (e.g. caking of a suspension), 4) 
change of organoleptic characteristics (e.g. appearance), 5) change of bioavailability, 6) 
appearance of an irritant or toxic degradation product (Tuleu, 2007). Interactions between 
drug substance and excipients may also induce instability (Florence and Attwood, 2006; 
Glass and Haywood, 2006).  
Extemporaneous preparations are often given arbitrary shelf lives or shelf lives based on 
published information (Tuleu, 2007). Compounders have to rely on drug-specific and 
general stability documentation and literature, but often have to estimate this information 
by considering the drug and its degradation mechanism, packaging container, the expected 
storage conditions, and the intended duration of therapy (The United States Pharmacopeial 
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Convention, 2008). Determination of the shelf life should be assessed conservatively, for 
example USP provides also maximum beyond-use dates for nonsterile solid and liquid 
formulations. 
2.4.1 Uniformity of dosage units 
Uniformity is tested in several ways in the European Pharmacopoeia (Table 2) (European 
Directorate for the Quality of Medicines & Health Care, 2013). The section on Uniformity of 
dosage units (2.9.40) contains the tests for content uniformity and mass variation, which are 
required to ensure the uniformity of dosage units: i.e. each unit in a batch should contain 
the labelled amount of the medicinal agent. Uniformity of content of single-dose 
preparations (2.9.6) is used to determine whether the individual contents of active 
substance are within the limits set with reference to the average content of the sample. 
Uniformity of mass of single-dose preparations (2.9.5) is required for capsules, powders 
and tablets. Oral liquid preparations supplied in multidose containers must comply with 
the test for Uniformity of mass of delivered doses from multidose containers (2.9.27).  
The lower the proportion of active ingredient, the more difficult it is to achieve 
acceptable dose uniformity in a powder mixture (Twitchell, 2007). A lower amount of active 
ingredient in capsules showed a higher percentage of nonconformity when compared to 
higher dosage in a study that examined the amounts of morphine, ursodeoxycholic acid, 
hydrocortisone, captopril, and nicardipine capsules compounded in a hospital pharmacy 
over a period of three years (Mathaut et al., 2006).  
The tablet dispersion method leads to wide variation of doses (Broadhurst et al., 2008). 
Dispersible aspirin tablets 75 mg were placed for three or five minutes in 10 ml of water 
and theoretical 7.5 mg (1 ml) or 15 mg (2 ml) doses were taken. However, all the doses 
withdrawn were less than required and never exceeded 76.5% of the intended dose. The 
white sediment on the bottom of the dispersion probably consisted of undissolved aspirin 
and excipients. 
Deicke and Süverkrüp (2000) investigated dose uniformity and redispersibility of three 
commercial erythromycin ethyl succinate oral liquids. The required volume of water was 
added to powder or granules and then the suspension was shaken vigorously with the 
apparatus. The samples were taken three times a day for two weeks. One of the products 
performed satisfactorily, one showed moderate shortcomings while the dose uniformity of 
two samples of the third product was clearly deficient. The problems seemed to be 
associated with poor wetting behaviour of the solids. Orr and Hill (1980) studied variation 
in 120 mg/5 ml doses of paracetamol suspension and found variation ranging from 74 mg 
to 173 mg in doses taken from one bottle with spoon and from 81 mg to 390 mg in doses, 
which were taken from 25 nearly empty bottles.  
The use of mass variation test to evaluate quality control of extemporaneously prepared 
microdose captopril capsules was claimed to be unreliable (Colucci et al., 1994). An analysis 
of captopril 1 mg capsules which had been compounded by triturating 25 mg tablets 
showed that capsules were within acceptable limits for weight variation test described in 
the USP but failed the test for content uniformity i.e. the amounts of captopril in capsules 
were 1.27 mg  0.31 mg. Instead, captopril 25 mg capsules compounded in the pharmacy 
passed the tests for uniformity of mass and uniformity of content (Marcatto et al., 2005). 
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Table 2. Uniformity tests of European Pharmacopoeia for hard capsules, oral powders (single-
dose) and liquid preparations for oral use.  
 
European 
Pharmacopoeia test 
Hard capsules Oral powders 
(single-dose) 
Liquid preparations 
for oral use 
Uniformity of dosage 
units (2.9.40)* 
API ≥25 mg and 
≥25%: Mass variation 
API <25 mg or <25%: 
Content uniformity 
API ≥25 mg and 
≥25%:  
Mass variation1 
Content uniformity2 
API <25 mg or <25%: 
Mass variation1 
Content uniformity2 
Solutions in single-dose 
container: Mass 
variation 
Others: Content 
uniformity 
Uniformity of content of 
single-dose 
preparations (2.9.6)** 
API <2 mg or <2% API <2 mg or <2% Single-dose 
suspensions 
Uniformity of mass of 
single dose 
preparations (2.9.5)** 
Required if Uniformity 
of content is not tested 
Required if Uniformity 
of content is not tested 
Single-dose solutions 
(modified test) 
Uniformity of mass of 
delivered doses from 
multidose containers 
(2.9.27) 
Not required Single dose container: 
Not required 
Required if supplied in 
multidose container 
Solutions and 
suspensions supplied in 
multidose containers 
*Primary test **Where justified or authorized 1Single component 2Multiple components 
2.4.2 Chemical stability 
Each active ingredient has to retain its chemical integrity and labelled potency within the 
specified limits (Allen, 2010a). A reduction of content down to 90% of theoretical value 
(with possible 95% confidence limits) is generally regarded as the maximum reduction 
acceptable (Mehta, 1993; Barnes, 2007).  
Chemical degradation reactions can be sub-divided into hydrolysis, oxidation, 
isomerisation, polymerisation, and photodegradation (Barnes, 2007). These can all cause a 
loss of potency of the drug, often accompanied by changes in the appearance of the product 
(e.g. discoloration, formation of a precipitate). Most drugs exist in the reduced form and 
thus are susceptible to oxidation (Chan, 2001). A suspension formulation may often be 
more stable than the same drug in a solution because much of the drug is protected within 
the insoluble particles (Barnes, 2007). 
The degradation of photolabile drugs depends on both the intensity and spectral 
distribution of the light source and is most common if they are exposed to ultraviolet light 
(Thoma, 1996; Florence and Attwood, 2006). Molecules that absorb wavelengths of sunlight 
or artificial light may become degraded (photolysis) (Florence and Attwood, 2006; Barnes, 
2007). In addition, photodegradation may also occur as a consequence of absorption of 
radiation by excipients, which transfer the absorbed energy to the drug (photosensitisers) 
(Florence and Attwood, 2006).  
Different numbers and structures of photodegradation products can be obtained by 
irradiating the drug in the solid state or in solution (Thoma, 1996). In the solid-state 
photodegradation only takes place at the surface and thus it happens more slowly than in 
solution (Thoma, 1996; Florence and Atwood, 2006). The rate of decomposition is 
influenced by the size and surface of particles, the colour and crystalline structure, and 
excipients. Different methods can be used to achieve protection from light, e.g. using 
coloured light-resistant containers, storage in the dark and coating tablets with a polymer 
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film containing ultraviolet absorbers or light protecting pigments. If the coating of the tablet 
is crushed, which is the case in extemporaneous preparation process, then photoprotection 
has to be assured with tinted packing materials.  
The determination of the shelf life of a formulated product needs to be performed on the 
actual product at a realistic storage temperature, normally at room temperature storage or 
in a refrigerator and this will often require the use of an accurate, specific, reproducible and 
stability-indicating analytical method, e.g. high-performance liquid chromatographic 
technique should be used (Hagan, 1994; Chan, 1999; Nahata, 1999b; Barnes, 2007; ICH 
Harmonised Tripartite Guideline, 2012). A specific protocol for testing the photostability of 
new drugs and products has been described in the ICH Guideline (European Medicines 
Agency CPMP/ICH/279/95, 1998). 
Lam (2011) described the lack of stability data in a study of 46 oral anticancer agents. He 
noted that only two of them were commercially available in an oral liquid dosage form and 
dispensing instructions for extemporaneous oral liquid formulation were available for 21 
drugs, but only 14 of them had been tested for chemical stability and only three included 
physical stability data. Pharmacokinetic data on bioavailability could be found for seven 
agents. Chan (2001) reported that captopril 1% solution compounded from pure drug 
powder was more stable than one compounded from tablets because the copper and iron 
present in tablet excipients acted as catalysts for oxidation. An isoniazid mixture 
compounded from tablets exhibited over 10% degradation after three days because of an 
incompatibility between isoniazid and lactose (Haywood et al., 2005). 
2.4.3 Physical stability 
Physical stability means that the original physical properties, including appearance, 
palatability, uniformity, dissolution and suspendability, have been retained (Chan, 2001; 
Allen, 2002). In powders, the physical changes indicating instability include caking instead 
of free flowing, discoloration and release of pressure upon opening (Allen, 2002). In 
capsules, there can be changes in the physical appearance or consistency, softening or 
hardening of the shell, or discoloration, expansion or distortion of the gelatin capsule may 
occur. Physical instability in suspensions is expressed as caking of sediment or particle 
growth, which leads to inaccuracy of dose, poor appearance and grittiness (Florence and 
Attwood, 2006; Attwood, 2007; Barnes, 2007; Billany, 2007). The adhesion of suspension 
particles to container walls has also been noted as a problem, particularly with low-dose 
drugs (Florence and Attwood, 2006). Temperature fluctuations may cause crystal growth in 
suspensions and freezing of suspensions may result in a particle size redistribution and 
potential difficulties in resuspending (Billany, 2007; Allen, 2008). Particle growth can be 
prevented by the addition of polymers or surfactants (Sinko and Singh, 2011). 
Physical stability of pharmaceutical suspensions is very important although it has been 
generally ignored in the area of extemporaneous preparations (Han et al., 2006). During the 
storage, the settled solid particles should not form a hard cake, but should be able to be 
readily dispersed into a uniform mixture with a moderate amount of agitation (Attwood, 
2007; Tuleu, 2007; Sinko and Singh, 2011). In addition, the suspension must not be too 
viscous otherwise it will not flow freely out of bottle or pass through a syringe.  
If the solid particles in the suspension are sufficiently small, i.e. surface area of the 
particles is large, they may be highly energetic and tend to regroup to reduce the surface 
free energy (Sinko and Singh, 2011). This type of flocculation creates light, fluffy 
conglomerates, which settle rapidly, form a large sedimentation volume and are easily 
resuspended (Florence and Attwood, 2006; Attwood, 2007; Billany, 2007; The United States 
Pharmacopeial Convention, 2008; Sinko and Singh, 2011). In flocculated systems, the liquid 
above the sediment is clear because all particles are associated with flocs. On the other 
hand, too rapid clearance of the supernatant in a flocculated system produces the risk of an 
inaccurate dose being administered (Florence and Attwood, 2006; Billany, 2007). Thus, for 
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this reason, it may be necessary to add suspending agents in order to retard sedimentation 
(Florence and Attwood, 2006; Billany, 2007; The United States Pharmacopeial Convention, 
2008; Sinko and Singh, 2011). 
In contrast, deflocculated particles settle slowly and form sediment and solid aggregates, 
and finally a cake that is difficult to resuspend (Sinko and Singh, 2011). Deflocculated 
suspensions have different sizes of particles and when the large ones settle, the small ones 
remain in a turbid supernatant and no clear boundary is formed. Controlled flocculation 
can be achieved with the desired surface charge, zeta potential, and can be produced with 
electrolytes, surfactants and hydrophilic polymers (coating of particles) or by adjusting the 
pH (Sinko and Singh, 2011).  
Redispersion of the suspension can be influenced also by the particle size and changes in 
viscosity according to Stokes’ equation:  
 
 
where v is the terminal velocity (cm/sec), d is the diameter of the particle (cm), I is the 
density of the particle, e is the density of the medium, g is the gravitational constant, and  
is the viscosity of the medium (poise) (Sinko and Singh, 2011).  
Hurtado and Moffett (2007) reported one case of a neonate readmitted with an 
arrhythmia because an amiodarone suspension had been incorrectly compounded and the 
solids had settled into a hard mass at the bottom of the container. Sotalol hydrochloride 
suspensions formulated with simple syrup/methylcellulose 1:2.4 vehicle displayed 
precipitation of particles and required more agitation than Ora-Plus/Ora-Sweet –
formulations in order that they would be redispersed (Sidhom et al., 2005). Sedimentation 
in extemporaneously prepared spironolactone suspension appeared within 8–10 minutes in 
suspension vehicles methylcellulose 2%/dextrose 70%, carboxymethylcellulose 4%/cherry 
flavoured glycol, ethanol 10%/simple syrup and in methylcellulose1%/simple syrup. Simple 
syrup, syrup NF is a solution of 85% w/v sucrose in purified water (Asiri et al., 2001). 
Instead, in methylcellulose 2%/simple syrup, the sedimentation only started in 25 minutes. 
Even after vigorous vortexing, zonisamide in simple syrup or in methylcellulose 0.5% 
tended to separate into two phases, resulting in sampling variations (Abobo, Wei and 
Liang, 2009). When hypromellose and methylcellulose suspensions of hydrochlorothiazide 
were compounded with different proportions of glycerol as the wetting agent, it was found 
that as much as 20% of glycerol was needed to achieve the correct dose to be administered 
and to remain stable (Santoveña, Hernánder-Paiz and Fariña, 2012). 
The range of stability testing should cover both organoleptic properties and physical 
properties and characteristics (Florence and Attwood, 2006). Firstly, the physical stability is 
assessed by visual inspection against a white and black background to rule out any changes 
in colour and appearance (Nahata, 1999b). In addition, suspension should be studied for 
uniformity of dose, ease of resuspending, settling, caking, crystal growth, viscosity, pH, 
odour and loss of volume (Allen, 2002; Tuleu, 2007). The rate of sedimentation, the final 
volume or height of the sediment, and the ease of redispersion of the product are assessed 
(Billany, 2007). Particle size of a suspension can be effectively characterized by the 
combination of widely available laser diffraction and microscopy techniques (Han et al., 
2006). Since caking requires time to develop it has been recommended that a short beyond-
use date should be considered for risky suspensions (Thompson, 2009c). 
2.4.4 Microbiological stability 
Pharmacopoeial requirements for microbiological quality of non-sterile oral preparations 
include: not more than 102 (maximum acceptable count is 200) aerobic microbes and not 
more than 101 (maximum acceptable count is 20) yeasts or moulds per gram or per millilitre 
in aqueous formulations, not more than 103 (maximum acceptable count is 2000) aerobic 
   (1) 
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microbes and not more than 102 (maximum acceptable count is 200) yeasts or moulds per 
gram or per millilitre in non-aqueous formulations and the absence of Escherichia coli in 
both types of dosage forms (European Directorate for the Quality of Medicines & Health 
Care, 2013).  
Hygienic production, sterilization and suitable preservatives are used to prevent the 
presence or growth of microorganisms in the product (Hodges, 2007). The factors impacting 
on the hygienic preparation of medicines have been described: the provision of a clean and 
controlled work area, prevention of cross contamination, risk assessment, materials, quality 
of water, formulation, and health, hygiene, clothing and training of the personnel 
(Pharmaceutical Inspection Convention, 2008; Finnisn Medicines Agency, 2007 and 2011; 
European commission, 2012). Incorrect storage and unhygienic use of the product may also 
spoil the product (Ghulam et al., 2007). 
Products containing sufficient water to permit bacteria or fungi growth are vulnerable to 
spoilage, in contrast, in dry conditions only spore-formers can survive well (Hodges, 2007). 
The presence of microorganisms and their metabolites can even impair the chemical or 
physical stability and the drug solubility by affecting the pH and efficacy of the 
preservative (Ghulam et al., 2007; Hodges, 2007; Tuleu, 2007). The occurrence of 
microbiological growth in aqueous medicines can affect the organoleptic characteristics of 
the product, produce turbidity, smell or taste, and can render the product unacceptable, 
harmful, or even toxic to the patient.  
It has been reported that over 50 patients died and almost 700 were diagnosed with a 
fungal infection after receiving a methylprednisolone acetate injection produced by the 
compounding center (Thompson, 2013). A serious eye infection was diagnosed in 5 patients 
who received bevacizumab repackaged into single-use syringes. 
Simple syrup can become contaminated with moulds although it is not susceptible to 
bacterial growth (Nahata, Pai and Hipple, 2003; Hodges, 2007). Methylcellulose 1%, with or 
without a preservative added to simple syrup BP in a ratio of 1:4 failed the BP quality 
assurance criteria (Ghulam et al., 2007). Multiple use of dosing devices may also be the 
source of contamination (Dockhorn et al., 2010). In English hospitals, a total 151 
formulations out of 256 different oral liquid formulations contained tragacanth as the 
suspending agent (Purkiss and Kayes, 1981). Alternatives had to be evaluated when it was 
found that there was a high incidence of microbial contamination by coliforms and, 
occasionally, by even salmonella species (Farley and Lund, 1976).  
The microbiological quality of the extemporaneous preparations can be tested in 
accordance with the European Pharmacopoeia although there are demands for an 
improved pharmacopoeia monograph when testing non-sterile extemporaneous 
formulations (Long et al., 2006; European Directorate for the Quality of Medicines & Health 
Care, 2013). In published studies microbiological examination is only sometimes performed 
with different techniques (Sidhom et al., 2005; Long et al., 2006; Brustugun et al., 2009). 
2.5 EXTEMPORANEOUS ORAL DOSAGE FORMS FOR PAEDIATRIC PATIENTS 
Medication with extemporaneous preparations in hospital is an acute multidisciplinary 
process where decisions need the input and co-operation between physicians, pharmacists 
and nurses, i.e. all of the professionals involved have a duty of care to the patient within 
their area of responsibilities (European Directorate for the Quality of Medicines & Health 
Care, 2013). Pharmacists are the only healthcare professionals formally trained in the art of 
compounding, thus the skills of the compounding pharmacists are needed to satisfy the 
individualized needs (McElhiney, 2003; Allen, 2006; Giam and McLachan, 2008). The 
pharmacist needs to take responsibility for ensuring that the extemporaneous medicine is of 
suitable quality, safe, stable and effective (Allen, 2006; Giacoia, Taylor-Zapata and Mattison, 
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2007b; Giam and McLachlan, 2008; Treadway, Craddock and Leff, 2007; Jackson and 
Lowey, 2010). The roles and responsibilities in different stages of the preparation process 
are presented in Table 3.  
 
Table 3. Model of roles and responsibilities in compounding process in hospital pharmacy in 
Finland (Helin-Tanninen, 2008). 
 
Handling 
state 
Chief 
pharmacist 
Pharmacist 
(master’s 
degree) 
Pharmacist 
(bachelor’s 
degree) 
Accredited 
technician 
Physi-
cian 
Nurse / 
pharmacist 
(bachelor’s 
degree) on 
ward 
Order     R S 
Design of 
product 
 R RS  AC CI 
Formulation A R RS    
Compounding  AC R I   
Packaging and 
labelling 
 AC AC R   
Final check A RAC R I   
Dispensing  AC R SI   
Storage on the 
ward 
 C C  A R 
Administration 
to patient 
 C   AR RSC 
R = responsible person, A = person to whom R is accountable, S = can be supportive, C = could be 
consulted, I = should be informed 
Nunn, Aindow and Woods (2012) wrote that ‚the process of compounding is not 
without danger and there may be alternative strategies such as dose-rounding, therapeutic 
substitution or manipulation of adult dosage forms so that compounding is a last resort‛. 
When there are no comprehensive published standards for compounding, decisions in the 
different steps of preparation process have to be made by using professional 
pharmaceutical skills and risk analysis (Figure 1) (Glass and Haywood, 2006; Tuleu, 2007; 
Helin-Tanninen, 2008).  
A risk assessment must be performed before deciding to extemporaneously prepare a 
medicine: to compound or not (Jackson and Lowey, 2010). Non-validated formula, narrow 
therapeutic index, long-term use and altered bioavailability are well-known serious risk 
factors when the use of a manufactured therapeutic alternative may be preferred (Glass and 
Haywood, 2006; Jackson and Lowey, 2010). The compounder is responsible for ensuring 
that the quality is built into the prepared product (Kastango, Trissel and Bradshaw, 2003; 
The United States Pharmacopeial Convention, 2008). The existence of standards, 
standardisation and rationalisation of products would help to improve product quality 
(Jackson and Lowey, 2010).  
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Licenced and labeled for 
paediatric use
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Commercial:
1) therapeutic alternative
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- pharmacopoeial formula
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Extemporaneous oral solid 
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Active pharmaceutical 
ingredient:
- pure drug substance
Active pharmaceutical 
ingredient:
-manipulation of commercial 
solid dosage form
Design of oral formula using 
scientific principles
- uniformity of content?
- stability?
- packaging and storage?
Packaging Labelling
Double checking 
of calculations
Quality control
Approval of the 
product
Dispensing
Yes Yes
No
No
Yes
Yes Yes
No
No Yes
No No
Yes Yes
Yes
No
Yes Yes
Yes Yes Yes Yes
No
Oral liquid
Oral suspension:
-single-dose
-multi-dose
Capsules
-emptied 
before use
No
Oral powders
No No
 
Figure 1. A management flow chart and decision pathway of compounding process for oral 
preparations (Helin-Tanninen, 2008). 
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Extemporaneous preparations can be compounded by a pharmacist from the authorised 
dosage form from industry-generated information, information from a pharmacopoeia or a 
peer-reviewed journal or national/hospital/published formulary, or, if not available, ‘ad 
hoc’ compounding from the authorised dosage form using the pharmacist’s knowledge and 
skill (Ernest et al. 2012). The formulations should be kept as simple as possible to minimize 
risks associated with the preparation process and possible incompatibilities (Jackson and 
Lowey, 2010; Sam et al., 2012; Santoveña, Hernánder-Paiz and Fariña, 2012).  
Correct calculations, accurate and precise measurements, appropriate formulation 
procedures and documentation are needed (Glass and Haywood, 2006). Documented 
preformulation studies include for example physical description, particle size, solubility, 
pKa, pH, stability, excipient toxicity, and other important characteristics (Nahata and Allen, 
2008; Allen, 2008). The formulator may have a difficult choice: to use excipients for which 
toxicity is known and thus predictable, or excipients, about which there is no safety data for 
children (Standing and Tuleu, 2005). Critical control points should be set into a preparation 
process at those steps at which a control measure is applied to eliminate a hazard or at least 
to reduce it to an acceptable level (Nahata and Allen, 2008; Allen, 2008). Batch sizes should 
be consistent with the volume of drug orders and the stability of the compounded product 
(ASHP reports, 1993). The pharmacist is responsible for defining a beyond-use date for the 
prepared product (Glass and Haywood, 2006). The finished compounded preparations 
should be analysed at an appropriate level in-house or this task can be outsourced to a 
contract laboratory (Nahata and Allen, 2008).  
Accurate measurement of the dose, acceptable taste and smell, and convenient 
administration are requirements in order to achieve patient compliance (Nunn and 
Williams, 2005; Tuleu, 2007; Allen, 2008; Sam et al., 2012). The objective of all of the quality 
assurance should be the assurance of the safety, protection and well being of the patient 
(Sharp, 2000). 
2.5.1 Active pharmaceutical ingredient 
The active pharmaceutical ingredient (API) of the extemporaneous formulation may be a 
drug substance of pharmacopoeial standard or it can be manipulated from a licensed 
formulation, including also its excipients (Brion, Nunn and Rietord, 2003; Tuleu, 2007; 
Nissen, Haywood and Steadman, 2009). Ideally, extemporaneous products should be 
compounded from pure drug substances, but access to suitable amounts of APIs is not 
always possible and can be cost-prohibitive and time-consuming for pharmacies even when 
the compounds are available (Cook, Ling and Lee, 2007). In order to reduce the need for 
high-risk manipulations of adult products, pharmaceutical manufacturers should make 
available their pure qualified active substances (European Medicines Agency, 2006). The 
reliability of supplies needs to be ensured. Chollet and Jozwiakowski (2012) found that 
eight of the ten API (hydroxyprogesterone caproate) samples did not meet the purity 
specifications required by FDA. One of the API samples was found to actually be glucose. 
More frequently, commercial dosage forms intended for adults are manipulated: tablets 
are crushed or capsules are opened and the contents are used (Allen, 2002; Brion, Nunn and 
Rieutord, 2003; Tuleu, 2007). Some manufacturers do not provide any information on their 
product for use in extemporaneous formulations, either because of potential legal issues or 
because the data are too complex to be made available (Nahata and Allen, 2008). The best 
ways to manipulate industrial dosage forms could be evaluated by the pharmaceutical 
industry e.g. recommendations given in a MA (Salunke et al., 2011). It has also been claimed 
that industry-verified extemporaneous preparations and extemporaneous formulations 
compounded by dispensing pharmacists to their own formula with limited quality 
assurance need to be differentiated. The position of industry-verified extemporaneous 
preparations could be the same as for other industrial products, which are reconstituted 
according to MA.  
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If the starting material is neither licensed nor of pharmacopoeial standard then a risk 
assessment must be undertaken (Jackson and Lowey, 2010). Crushing of sustained-release 
tablet or capsule may increase toxicity or increase the risk of ADRs, since it involves 
breaking of enteric coat, film coat or delayed release coat which protects an acid-labile or 
light-sensitive active ingredient or controls the release of active ingredient, and thus can 
decrease efficacy or alter drug absorption (Birdsall and Uretsky, 1984; Mitchell and 
Pawlicki, 1992; Haywood and Glass, 2007; Nissen, Haywood and Steadman, 2009). The 
coating or film on an oral solid dosage form may also offer protection against local 
irritation, mask an unacceptable taste or prevent a potential hazard from a cytotoxic or 
teratogenic drug (Nissen, Haywood and Steadman, 2009; Jackson and Lowey, 2010).  
The resulting powder may be dissolved or suspended with various excipients in order to 
produce an oral liquid medicine, or it may be redistributed into smaller strength capsules 
or powder papers after dilution with some inactive ingredient (Brion, Nunn and Rieutord, 
2003; Tuleu, 2007). USP standards for pharmaceutical preparation require that the amount 
of API has to be equal to 90% to 110% of the intended dose (The United States 
Pharmacopeial Convention, 2008; Allen, 2010a). If there is wide variability of actual 
allowable range of the API (i.e. between 90% and 110%) in the manufactured product as the 
source of the drug, the compounded preparation could fail to meet specifications (Nahata 
and Allen, 2008; Allen, 2010a).  
2.5.2 Excipients 
Thousands of different excipients are used in different medicines (Haywood and Glass, 
2011). Excipients may be added for various reasons, to increase the bulk, add desirable 
colour, mask the unpleasant taste and smell, protect, support or enhance stability and 
facilitate creating a uniform mixture of the active ingredient in the final preparation (Pawar 
and Kumar, 2002; Haywood and Glass, 2011).  
In recent years, excipients have proved to be anything but inert (Table 4) (Noerr, 2000; 
Haywood and Glass, 2011). Maximum tolerated doses for excipients have often determined 
by animal safety testing but then extrapolated for use in adults (Ernest et al., 2007). Preterm 
or term newborns, and children may well be exposed to a variety of excipients present in 
the medicines that are essential for the treatment of illnesses, especially if they are critically 
ill infants receiving continuous infusions of medicines (Nahata, 2009). In an Estonian study 
Lass (2012) found that almost all (97%) treated hospitalised neonates received medicines 
with at least one potentially harmful excipient. The daily intake of some excipients may 
exceed the proposed maximum acceptable daily intake per kilogram of body weight for 
adults (Nahata, 2009). Dose-related adverse effects of excipients are of particular concern in 
the preterm newborn, low-birthweight neonates and infants, this being attributable to the 
immaturity of hepatic and renal function (Tuleu, 2007). It has been recommended that the 
ideal preparations for neonates and particularly premature babies should be free of 
preservatives and flavouring and colouring agents (Lund, 1994). In addition, European and 
United States Paediatric Formulation Initiatives (PFI)s have started to create the STEP 
(Safety and Toxicity of Excipients for Paediatrics) database (Salunke, Giacoia and Tuleu, 
2012). 
Very small amounts of active ingredients often require a carrier to ensure their uniform 
distribution in the dispensed product, and to guarantee an accurate dose (Pawar and 
Kumar, 2002; Haywood and Glass, 2011). Bulk fillers contribute to the product’s uniformity, 
stability, flow characteristics and compressibility (Pawar and Kumar, 2002). Lactose is often 
used as a filler or diluent in tablets and capsules, and to a more limited extent in infant 
formulas (Rowe et al., 2012). However, lactose, a disaccharide of glucose and galactose is 
absorbed after hydrolysis by the intestinal enzyme, lactase (Pawar and Kumar, 2002). 
Microcrystalline cellulose, which is derived from purified wood cellulose, is primarily used 
as a binder and diluent in oral tablet and capsule formulations (Pawar and Kumar, 2002; 
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Rowe et al., 2012). It is generally believed that microcrystalline cellulose is safe and is not 
absorbed into the systemic circulation after peroral administration (Kotkoskie et al., 1996; 
Rowe et al., 2012). However, some studies from 1970’s, using rats, dogs and pigs, have 
indicated that persorption of microcrystalline cellulose may occur after per oral 
administration (Pahlke and Friedrich, 1974 and 1975; Seidemann, 1976).  
Colloidal celluloses like hypromellose and methylcellulose are used as suspending 
agents in liquid preparations (Pawar and Kumar, 2002). Both are regarded as non-toxic and 
non-irritant materials, although excessive consumption orally may have a laxative effect. 
Purified water is the most commonly used solvent in liquid preparations (Pawar and 
Kumar, 2002; Rowe et al., 2010). It should be remembered that water may serve as a culture 
medium for bacteria and fungi (European Directorate for the Quality of Medicines & 
Health Care, 2013).  
The antimicrobial preservative needs to be selected so that it will inhibit the growth of 
the likely microorganisms, and it should be in an undissociated form for penetration into 
microorganisms (Nahata and Allen, 2008). Furthermore, it should dissolve sufficiently in 
water, be nonirritating and nonsensiting, and have adequately stability and compatibility. 
The use of preservatives like benzyl alcohol and benzoic acid may lead to life threatening 
toxicity in paediatric patients when multiple doses of preserved medications are 
administered (Glass and Haywood, 2006).  
It may be difficult to mask the taste of compounds with high solubility in liquid 
preparations (Allen, 2002; Davies and Tuleu, 2008; Cram et al., 2009). Even a small amount 
of solubilized drug in a suspension can trigger poor palatability. The age-related differences 
in the taste and smell have to be taken into account when designing good palatability: 
acceptable initial taste, after-taste, smell and texture for oral drug preparation (Nahata 
1999d; Pawar and Kumar, 2002; Davies and Tuleu, 2008). For example viscous vehicles 
enhance the mouth feel and improve the perceived flavour of oral liquids by reducing the 
contact of the drug with the taste buds (de Villiers, 2009a). Flavours are not elaborated 
further in this review. 
 
Table 4. Examples of reported adverse effects caused by excipients especially in children. 
 
Excipient Adverse effect Reference 
Antimicrobial preservatives: 
Benzalkonium 
chloride 
Dose-related bronchoconstriction, cough, burning 
sensation, occasionally facial flushing, pruritus 
American Academy 
of Pediatrics, 1997; 
Tuleu, 2007 
Benzoic acids 
and benzoates 
Displacement of bile from albumin binding sites in 
premature neonates, ―gasping syndrome‖ 
Kumar, Rawlings 
and Beaman, 1993; 
Tuleu, 2007 
Benzyl alcohol A number of neonatal deaths and severe respiratory and 
metabolic complications, neurologic symptoms, 
bronchitis, haemoptysis, kernicterus, hypersensitivity 
reactions (rare) 
Accumulation, leading to neonatal cardiovascular 
collapse, ―gasping syndrome‖ and 20 deaths in low-
birth-weight neonates with dose of 99-234 mg/kg/day 
Gershanik et al., 
1982; American 
Academy of 
Pediatrics, 
Committee on Fetus 
and Newborn and 
Committee on 
Drugs, 1983; 
American Academy 
of Pediatrics 1997; 
Noerr, 2000 
Boric acid Is not used internally owing to its toxicity: death from 
ingestion of <5g in young children  
Rowe et al., 2012 
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Chloroform Carcinogenic 
In UK: previously usual preservative in paediatric 
formulations, now maximum content 0.5%. The use as a 
preservative has been prohibited in USA since 1976. 
Purkiss and Kayes, 
1981; Hanson, 
2003; Tuleu, 2007 
Parabens Skin sensitization and cross-sensitization with each 
other 
Concern has been expressed over the use of 
methylparaben in infants’ parenteral products because 
bilirubin binding may be affected, which is potentially 
hazardous in hyperbilirubinemic neonates 
The WHO has set an estimated total acceptable daily 
intake for methyl-, ethyl-, and propylparabens at no 
more than 10 mg/kg 
Kumar, Rawlings 
and Beaman, 1993; 
Tuleu, 2007; Rowe 
et al., 2012 
Sodium 
benzoate 
Nonimmunological contact urticaria 
It has been recommended that sodium benzoate 
injection should not be used in neonates 
The WHO acceptable daily intake of total benzoates, 
calculated as benzoic acid, has been estimated up to 5 
mg/kg 
Rowe et al., 2012 
Sodium borate Damaged skin, severe toxicity (vomiting, diarrhoea, 
erythema, CNS depression, kidney damage) especially in 
children 
Lethal oral intake 5g in children 
Rowe et al., 2012 
Thiomersal Hypersensitivity (at 0.1% concentration in children). Ten 
out of 13 children died as a result of treatment with 
topical tincture containing thiomersal 
Rowe et al., 2012 
Antioxidants 
Propyl gallate Methaemoglobinaemia in neonates, sensitizing in 
animals 
Nitzan, Volovitz and 
Topper, 1979; 
Ernest et al., 2007 
Sulphites Wheezing, dyspnoea, bronchospasm (especially in those 
with a history of asthma or atopic allergy), anaphylaxis, 
urticaria, itching 
In Europe, the acceptable daily intake of sodium 
metabisulphite and other sulphites used in foodstuffs 
has been set at no more than 3.5 mg/kg, calculated as 
sulphur dioxide 
American Academy 
on Pediatrics, 1997; 
Rowe et al., 2012 
Thymol Respiratory arrest, nasal congestion and edema 
(reported in newborn) 
Not for children under 5 years 
Rowe et al., 2012 
Bulk fillers: 
Lactose Diarrhoea, malabsorption, vomiting, flatulence (in 
patients with lactose-intolerance) 
Jaundice, hypoglycaemia, CNS symptoms, cataracts (in 
patients with galactosemia)  
Kumar, Rawlings 
and Beaman, 1993; 
Kumar et al., 1996; 
American Academy 
on Pediatrics, 1997; 
Tuleu, 2007 
Mannitol Anaphylactic reactions Kumar et al., 1996 
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Colouring agents: 
Azo dyes  Anaphylactic reactions, angioedema, asthma, urticaria, 
contact dermatitis, rhinitis, hyperkinesis in hyperactive 
patients, cross-sensitivity with acetylsalicylic acid, 
sodium benzoate and indomethacin (tartrazine FD&C 
yellow5 = E102, sunset yellow FD&Cyellow6 = E110), 
bronchoconstriction (FD&C4 Ponceau Sx), contact 
dermatitis (FD&CRed36, FD&C17) 
Kumar, Rawlings 
and Beaman, 1993; 
Kumar et al., 1996; 
American Academy 
on Pediatrics, 1997; 
Pawar and Kumar, 
2002 
Carmine Allergic cheilitis, asthma Kumar, Rawlings 
and Beaman, 1993 
Quinoline 
yellow 
Contact dermatitis  Kumar, Rawlings 
and Beaman, 1993; 
Pawar and Kumar, 
2002 
Triphenyl-
methane dyes 
Bronchoconstriction in asthmatic patients (FD&C blue1 = 
E133), erythema multiforme-like skin rash (fast green 
FCF: FD&C green3) 
Kumar, Rawlings 
and Beaman, 1993; 
Kumar et al., 1996; 
Pawar and Kumar, 
2002 
Xanthine dyes Potent photosensitizer (eosin: FD&C red22), potent 
photosensitizer, carcinogenicity (erythrosine: FD&C3 = 
E127), urticaria, syncopy, anaphylaxis, angioedema 
(fluorescein FD&C yellow7) 
Kumar, Rawlings 
and Beaman, 1993; 
Pawar and Kumar, 
2002 
Surfactants, suspending and solubilizing agents and solvents: 
Carrageenan Induces inflammatory responses in animals Ernest et al., 2007 
Ethanol Accumulation of acetaldehyde, lethal dose 3 g/kg  
In the USA, the maximum quantity of alcohol included in 
over-the-counter medicines is: 10% v/v for use by 
individuals of 12 years of age and older, 5% v/v for 
children aged 6–12 years of age, and 0.5% v/v for 
children under 6 years of age  
In Europe, there are no limits set 
American Academy 
of Pediatrics, 
Committee on 
Drugs, 1984; Tuleu, 
2007; Pawar and 
Kumar, 2002; Rowe 
et al., 2012 
 
Glycerol >40% in volume: mucositis, diarrhoea, electrolyte 
disturbances 
Pawar and Kumar, 
2002 
Liquid paraffin Lipoid pneumonia caused by aspiration 
Should not be used in very young children 
Rowe et al., 2012 
Polyethylene 
glycol 
Renal failure (in 1937, children treated with 
sulphanilamide elixir developed renal failure traceable to 
ethylene glycol which had been used as a solvent), 
poisoning where 107 patients died 
The WHO has set an estimated acceptable daily intake of 
polyethylene glycols at no more than 10 mg/kg 
Ernest et al., 2007; 
Rowe et al., 2012 
Polysorbate Hypersensitivity 
Serious adverse effects (E-Ferol syndrome: 
thrombocytopenia, renal dysfunction, hepatomegaly, 
cholestasis, ascites, hypotension and metabolic acidosis, 
including 38 deaths in low-birthweight infants) 
The WHO has set an estimated acceptable daily intake 
at no more than 25 mg/kg 
Alade, Brown and 
Paquet, 1986; 
Balisteri, Farrell and 
Bove, 1986; Tuleu, 
2007; Ernest et al., 
2007; Rowe et al., 
2012 
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Povidone Anaphylactic reaction Tuleu, 2007 
Propylene 
glycol 
One-third as intoxicating as ethanol 
Accumulation: hyperosmolality, effects on central 
nervous system, ototoxicity, cardiac arrhythmias, 
seizures, osmotic laxative effects, contact dermatitis, 
lactic acidosis (especially in neonates and children <4 
years of age) 
Acceptable daily intake up to 25 mg/kg  
Not recommended for children <4 years (limited alcohol 
dehydrogenase). Half-life 17h in neonates (5h in adults). 
Glasgow et al., 
1983; American 
Academy of 
Pediatrics, 1997; 
Noerr, 2000; Tuleu, 
2007; Kulo, de 
Hoon and Allegaert, 
2012; Rowe et al., 
2012 
 
Sweetening and flavouring agents: 
Aspartame Headache, grand mal seizures, memory loss, 
gastrointestinal symptoms, angioedema, pruritus, 
urticaria, granulomatous panniculitis, cross reactivity 
with sulphonamides, renal tubular acidosis (large 
quantities) 
Potentially toxic metabolites methanol, aspartic acid and 
phenylalanine; aspartic acid is neurotoxic and 
epileptogenic 
Phenylalanine is harmful in patients with 
phenylketonuria 
Kumar, Rawlings 
and Beaman, 1993; 
Kumar et al., 1996; 
American Academy 
of Pediatrics, 1997; 
Pawar and Kumar, 
2002; Rowe et al., 
2012; Tuleu, 2007 
Fructose Hypoglycaemia (in patients with fructose intolerance) Kumar et al., 1996 
Menthol Hypersensitivity reactions, systemic allergic reactions Kumar, Rawlings 
and Beaman, 1993 
Peppermint oil Atrial fibrillation, muscle pain, cooling or burning 
sensations 
Kumar, Rawlings 
and Beaman, 1993 
Saccharin, 
saccharine 
sodium 
Irritability, hypertonia, insomnia, opisthotonus and 
strabismus, urticaria, pruritus, nausea, diarrhea, 
tachycardia, papular skin eruptions, wheezing, cross 
reactivity with sulphonamides 
Approved for children >3 years 
American Academy 
of Pediatrics, 1997; 
Kumar, Rawlings 
and Beaman, 1993, 
Pawar and Kumar, 
2002; Tuleu, 2007 
 
Sodium 
cyclamate 
Photosensitization, eczema, dermatitis, pruritus, 
incidence of bladder cancer increased in rats 
Use is restricted in many countries 
Kumar, Rawlings 
and Beaman, 1993 
Sorbitol  Abdominal pain, decreased absorption of active drug, 
flatulence, osmotic diarrhoea (large amounts) 
Kumar, Rawlings 
and Beaman, 1993; 
Kumar et al., 1996; 
Tuleu, 2007 
Sucrose Tooth decay 
Cariogenicity, hyperglycaemia, increased degradation of 
active drug, allergic reactions (very rare) 
Kumar, Rawlings 
and Beaman, 1993, 
Kumar et al., 1996; 
Pawar and Kumar, 
2002, Tuleu, 2007 
Xylitol Osmotic diarrhea (large amounts) Kumar et al., 1996 
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2.5.3 Manipulation of oral solid dosage forms 
Instead of compounding, tablets are sometimes manipulated: cut into halves, quarters or 
smaller segments on the ward to obtain appropriately sized dosage units for children or 
cost savings (McDevitt, Gurst and Chen, 1998; Brion, Nunn and Rieutord, 2003; Hill et al., 
2009; Navarro, 2009). The extent of ward-based segmenting of tablets is unknown, but it is 
believed to be extensive and might well occur if pharmacies have neither the time nor the 
capability to provide other options (Brion, Nunn and Rieutord, 2003).  
A tablet dispersion method is normally used on the wards (Haywood and Glass, 2007). 
The tablet, tablet segments or contents of capsule are placed in a cup of water or oral 
syringe and stirred by swirling a device until the contents have dispersed, and this is 
administered immediately to the patient (Dupuis and Armstrong, 1998; Haywood and 
Glass, 2007). An aliquot of the dispersion can be used only if the medication is soluble: for 
insoluble drugs, this method provides highly variable doses without the use of suspending 
agents (Standing and Tuleu, 2005).  
Subdivision of tablets should be assessed and authorised by the competent authority 
(European Directorate for the Quality of Medicines & Health Care, 2013). Tablets comply 
with the test if not more than one individual mass of halves from 30 tablets is outside the 
limits of ±15% of the average mass and if no individual mass is outside the limits ±25% of 
the average mass. Unequal breaking of tablets may result in significant dose variability 
(Horn, Kuhn and Kanga, 1999; Marriott and Nation, 2002; Teng et al., 2002; van Santen, 
Barends and Frijlink, 2002). This may be clinically significant for drugs, which have a 
narrow therapeutic range or short half-life (Marriott and Nation, 2002; Hill et al., 2009).  
The degree of inaccuracy seems to be associated with tablet size, thickness, shape, 
coating and type of score line (Sedrati et al., 1994; Marriott and Nation, 2002, van Santen, 
Barends and Frijlink, 2002). It has been reported that oval 10-mm tablets with deep scores 
on both sides were most accurate in manual splitting (McDevitt, Gurst and Chen, 1998). 
Even when commercial tablet cutters are used, the accuracy of splitting may be variable 
(Sedrati et al., 1994; Horn, Kuhn and Kanga, 1999; Marriott and Nation, 2002; Teng et al., 
2002). The tablet-splitting device was most accurate with larger (> 600 mg) tablets that were 
coated, and had an oblong shape and flat edges (McDevitt, Gurst and Chen, 1998). 
Powdering and fragmentation during splitting of tablets can also be a source of loss of 
mass, from 1.1% to 14% when breaking tablets into halves and up to 27% when breaking 
them into quarters (van Santen, Barends and Frijlink, 2002).  
Fewer than 50% of the splitted clonidine 0.1 mg and captopril 12.5 mg tablet quarters 
were within ±15% acceptance limits in the mass variation test (Horn, Kuhn and Kanga, 
1999). In another study, over 40% of manually split tablet halves (n = 1752) deviated from 
ideal weight by more than 10% and over 10% deviated by more than 20% (McDevitt, Gurst 
and Chen, 1998). When a commercial splitter was used, nearly 40% of the portions (n=102) 
deviated by over 10%. Greater than 15% variation of the intended mean half-tablet weight 
was found in certain products when they were split in half with a commercial splitter 
(Sedrati et al., 1994). Teng et al. (2002) found that of the 11 tablet products splitted with 
single-edged razor blade (10 tablets for each product), only three products passed the 
uniformity of dosage units test of the United States Pharmacopeia. Finally, all three hand-
split tablets failed the test. 
In a study performed with 30 tablets of warfarin sodium 5 mg, metoprolol succinate 200 
mg, lisinopril 40 mg, metoprolol tartrate 25 mg, simvastatin 80 mg and citalopram 40 mg it 
was found that dose variation exceeded USP specification for more than 30% of sampled 
half-tablets for the warfarin sodium, metoprolol succinate and lisinopril, and from 10% to 
17% for metoprolol tartrate, simvastatin and citalopram (Hill et al., 2009). The drug content 
variation in half-tablets was greater for nonscored tablets as compared with scored tablets, 
but the loss of mass after splitting was only about 1%. The results also appeared to indicate 
that the drug had been uniformly dispersed within tablet. 
25 
 
 
The tablet dissolution rate and absorption characteristics of coated, enteric-coated and 
controlled-release tablets may be affected when tablets are split (Marriott and Nation, 2002; 
Sam, 2002). A controlled-release tablet that has been split may produce overdose: this has 
been suspected of causing to a number of adverse effects (Sam, 2002). Splitting may also 
expose the taste of the drug, which had originally been masked in the coated tablet 
(Marriott and Nation, 2002).   
2.5.4 Compounding of oral powders 
Oral solid dosage forms that are compounded for paediatric medication are mainly oral 
powders and capsules (Thompson, 2009a and 2009b). Oral powders (i.e. single-dose 
powders, divided powders, powder papers, sachets, chartulae), one of the oldest dosage 
forms, are preparations consisting of solid, loose, dry particles of varying degrees of 
fineness (Gennaro, 1990; Thompson, 2009a; European Directorate for the Quality of 
Medicines & Health Care, 2013). They contain one or more active substances, with or 
without excipients such as lactose or microcrystalline cellulose. Different strengths may be 
required to medicate children of different ages (Nahata, 1999a; Nunn, 2003). 
Each dose of powder is weighed separately to a small folded waxed powder paper and 
thus oral powders are more time consuming to be compounded than capsules or oral 
liquids (Sandell, 1983; Nahata, 1999a; Allen, 2001; Allen, 2002; Thompson, 2009a). In the 
pharmaceutical industry, modern packaging materials of foil and plastic laminates had 
replaced paper wrappings because of their superior protective qualities (Summers, 2007). 
Oral powders generally represent a stable dosage form only for as long as they are 
protected from moisture and heat in tight containers (Gennaro, 1990; Allen, 2001; Allen, 
2002; Thompson, 2009a).  
The properties of a solid must be understood and evaluated to allow proper handling 
and manipulation of the material (Thompson, 2009a). The properties of powders are related 
to the size and surface area of the particles (Allen, 2002). Particles larger than 250 μm are 
usually relatively free flowing but as the size falls below 100 μm, powders become more 
cohesive and if the particle size is less than 10 μm, then powders are usually extremely 
cohesive and they resist flow (Staniforth and Aulton, 2007). Small particles present a greater 
surface area to the atmosphere and are thus more reactive to absorb gases like carbon 
dioxide (Allen, 2001).  
A drug powder or a powder from commercially available crushed tablets or opened 
capsules may be diluted with excipient and redistributed into smaller strength powder 
papers (Nunn, 2003; Glass and Haywood, 2006). The first step in the powder preparation is 
to ensure that all the components of the mixture are in the same particle size range to 
prevent stratification of large and small particles (Gennaro, 1990; Allen, 2001; Allen, 2002; 
Thompson, 2009a). If one decreases the particle size, then more particles will be present in a 
unit dose and the probable variation in content may be reduced (Twitchell, 2007). Small 
particles dissolve faster due to their large surface area, and thus these kinds of powders 
tend to have a rapid onset of action (Allen, 2002; Thompson, 2009a). 
In small-scale preparation, comminution involves mainly manual methods, e.g. 
trituration, levigation and pulverization by hand (Allen, 2002). Trituration refers to the 
process of rubbing substances down into fine particles in a mortar with a pestle or 
intimately mixing of fine powders in a mortar (Gennaro, 1990). In levigation, a paste is first 
created in a mortar by the addition of a suitable nonsolvent to the solid. Pulverization is the 
process of reducing the state of gummy (e.g. camphor) or it can consist of reagglomerating 
or grinding-resist solids with the aid of small amount of alcohol or some other volatile 
solvent. 
The lower the proportion of active component present in the mixture, the more difficult 
it is to achieve an acceptably low deviation in the active content (Twitchell, 2007). In order 
to conduct trituration in a mortar, the pestle is held firmly and downward pressure is 
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exerted with it while the pestle is moved in larger concentric circles (Thompson, 2009a). 
This is done by starting at the center of the mortar, moving outward to the sides of the 
mortar and then back to the center. If the powder has become compacted onto the sides of 
the mortar, it is continually removed by scraping it with a spatula. 
Geometric dilution is used to ensure that small quantities of ingredients are uniformly 
distributed throughout the powder mixture (Gennaro, 1990; Allen, 2002; Thompson, 2009a). 
This is started with the ingredient in the smallest quantity. The volume of powder equal to 
the volume of powder mixture in the mortar is added and triturated with a pestle to a 
uniform mixture until all the powder ingredients have been added (Allen, 2002; Thompson, 
2009a). If the powder is too fluffy, it can be compacted slightly by the addition of a few 
drops of alcohol, water or liquid paraffin (Allen, 2002). Mortars need to be nonporous so 
that no drug substance remains in the pores to decrease the dose or to contaminate the next 
product to be compounded (Allen, 2002). Some powder will always be lost during the 
blending process (Thompson, 2009a).  
Typically, the powder mixes contain particles that differ in size, shape and density and 
thus they may become segregated during mixing or storing and shipping (Allen, 2002; 
Twitchell, 2007). Larger particles separate at the edge of the powder heap while smaller 
particles tend to fall through the voids between larger particles and move to the bottom of 
the mass (Twitchell, 2007). Even in cases where particle sizes are similar, the more dense 
particles will move downwards and segregation will cause an increase in content variation 
(Allen, 2001; Twitchell, 2007). The use of excipients that have a similar density to the active 
component is one approach to minimize the risk of segregation.  
Single-dose powders are weighed individually with a balance which is appropriate and 
accurate for the intended purpose (Thompson, 2009a). An intermediate amount of powder 
of 200 mg to 500 mg per packet is desirable. In addition, minimum weights of 120 mg and 
maximum of 500 mg of dose powder have been described (Sandell, 1983; Lund, 1994). The 
weight of 200 mg is recommended because this amount can be weighed and calculated 
easily (Marriott et al., 2010).  
Powders should never be ingested without first moistening them because of the possible 
risk of aspiration or choking (Pagliaro, 2002). Usually the powders are administered in a 
liquid such as water or milk, in some other beverage or soft food if no incompatibilities are 
present (Allen, 2002; Glass and Haywood, 2006). The taste or caustic nature of the active 
drug may limit their use (Allen, 2002). 
2.5.5 Compounding of hard gelatin capsules 
While oral powders are standardized by mass, capsules are standardized by volume. The 
active substances are filled into one of the sections of the hard capsule shell that is then 
closed by slipping the other section over it (European Directorate for the Quality of 
Medicines & Health Care, 2013). Normally hard capsules are swallowed as a whole, but 
when they need to be administered to infants, the compounded capsules may be opened 
before administration (Allen, 1999; Allen, 2002; Pagliaro, 2002). The contents are gently and 
adequately mixed with a small amount of suitable liquid or soft food to avoid inhaling the 
powder into the lungs (Pagliaro, 2002). 
The capsule size selected should be slightly larger than needed to hold the drug 
substance and sufficient excipients are added to fill the capsule shell (Allen, 2002). For 
children, the capsules with numbers 1–5, i.e. capacities of 0.48–0.13 ml, are normally used 
(Allen, 2002, Thompson, 2009b). Hard gelatin capsule shells normally contain about 12–16% 
water and thus they do not protect hygroscopic materials from atmospheric water vapour 
since moisture can diffuse through the gelatin wall (Allen, 2002; Rudnic and Schwartz, 
2006; Jones, 2007, Thompson, 2009b). The excipients present in capsule formulation can 
have a significant effect on the rate of dissolution of poorly soluble and hydrophobic drugs 
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(Ashford, 2007). An increase in packing density of the encapsulated mass is believed to 
decrease liquid permeability and also to reduce the dissolution rate. 
Manually operated capsule filling devices are suitable for small-scale production (Allen, 
2002). Feton® from Belgium, Labocaps® from Denmark or Torpac® from USA consist of sets 
of plates which have predrilled holes to take 30–100 capsules (Jones, 2007). Smaller 
quantities can be prepared by blocking off unused holes (Allen, 1999). Empty capsules are 
fed into the holes, the bodies are locked by means of a screw and the caps are removed 
(Jones, 2007). The powder that should have good flow properties is spread with spatula so 
that it fills the bodies evenly. Then the capsules are closed. 
2.5.6 Compounding of oral liquids 
Liquid preparations for oral use include oral solutions and oral suspensions (European 
Directorate for the Quality of Medicines & Health Care, 2013). For infants and children 
under 5 years old, pharmaceutical liquids are traditionally preferred for oral administration 
(Allen, 2008). Multidose oral liquids provide a range of doses but they require a validated 
amount of preservatives and may be inaccurate in measuring of required dose (Sam et al., 
2012). Instead, a single-unit oral liquid needs no measuring of dose but it provides only 
limited dose flexibility.  
Liquid preparations have advantages of ease of administration compared to solid dosage 
forms, but usually dissolved drugs are more susceptible to degradation than when they are 
in the solid state (Tuleu, 2007; Jackson and Lowey, 2010). Solutions and elixirs can be 
irritating to the gastric mucosa and may be associated with some ADRs like nausea and 
vomiting (Pagliaro, 2002). Gastric irritation and osmotic diarrhoea may result from 
administering medicines that increase the osmolality of the gastrointestinal contents. An 
osmolality of 330–350 mOsm/kg is considered as most appropriate for enteral 
administration (Polo et al., 2007).  
Oral liquids are comparatively quick to compound (Brion, Nunn and Rieutord, 2003). A 
small-scale preparation of an extemporaneous liquid dosage form from a tablet or capsule 
generally involves grinding of the tablets or emptying the contents of the capsules into a 
mortar (Nahata and Allen, 2008; The United States Pharmacopeial Convention, 2008; Jew, 
Soo-Hoo and Erush, 2010). To ensure uniformity of dose, it is recommended to add 
suspending agents to the vehicle whether or not the API in the tablet is soluble, because of 
the possible absorption of the drug to insoluble excipients in the tablets (Jackson and 
Lowey, 2010). In addition, a pharmaceutical suspension is an appropriate dosage form for 
administering insoluble or poorly water-soluble drugs (Ashford, 2007; The United States 
Pharmacopeial Convention, 2008). The suspension consists of two phases where finely 
divided insoluble particles, generally greater than 1μm, are uniformly dispersed 
throughout the liquid, usually an aqueous vehicle (Attwood, 2007; The United States 
Pharmacopeial Convention, 2008). The product must remain sufficiently homogenous for at 
least the period between shaking the container and measuring the required amount 
(Billany, 2007). 
The particle size of the powder may first need to be reduced using a mortar and pestle in 
order to obtain small, uniform drug particles (The United States Pharmacopeial 
Convention, 2008). Many suspensions have particle sizes ranging from 1 to 100 µm, in 
better suspensions from 1 to 50 µm. Fine particles are more easily dispersed throughout the 
vehicle, settle more slowly and are less likely to cake.  
The initial dispersion and proper wetting of an insoluble powder in a vehicle is an 
important step (Thompson, 2009c; Sinko and Singh, 2011). Hydrophilic materials can be 
first wetted with water-miscible liquids and hydrophobic substances with nonpolar liquids 
or surfactant (The United States Pharmacopeial Convention, 2008; Thompson, 2009c; Sinko 
and Singh, 2011). The incorporation of hydrophilic colloids like cellulose derivatives, 
xanthan gum and tragacanth will both increase the viscosity and protect the solid 
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hydrophobic particles with a multimolecular layer and thus impart a hydrophilic 
characteristic, which promotes wetting (Billany, 2007). A small quantity of selected vehicle 
is then added to form a paste (The United States Pharmacopeial Convention, 2008). Then 
additional vehicle is added in geometric portions and mixed to the desired volume. Small 
quantities of the added vehicle and good mixing are important to avoid the formation of 
lumps (van Schijndel, 2002). Formulating a stable suspension often requires more excipient 
content as compared with solid dosage forms (Standing and Tuleu, 2005). Friendly, the ease 
of redispersion in parallel with the uniformity of dose needs to be tested (Tuleu, 2007). 
For poorly soluble drugs like nifedipine, dissolution is often the limiting step in 
absorption (Tuleu, Grangé and Seurin, 2005). A large surface of the dispersed drug in the 
suspension will enhance dissolution (Attwood, 2007). In contrast to the equivalent solid 
dosage forms like powder-filled hard gelatin capsules, dissolution of all drug particles 
begins immediately on dilution of the suspension in gastrointestinal fluids (Ashford, 2007; 
Marriott et al., 2010).  
The dosage can be measured from a single strength preparation by using an oral syringe 
(Brion, Nunn and Rieutord, 2003). Since stability data in pharmacy-prepared prefilled 
plastic syringes is limited, the storage of drugs needs to be minimized (Tucro, 1994). New 
guidelines on the standards required for the preparation of non-sterile liquids in healthcare 
establishments have recommended the use of closed systems for processing and transfer to 
the wards to protect the product from contamination (Pharmaceutical Inspection 
Convention, 2008). 
Oral syringes provided much higher dosing accuracy in comparison with the specifically 
designed measuring spoons when the volumes of 1.25, 2.5 and 5 ml were withdrawn 
corresponding to ¼, ½ and full spoon (Dockhorn et al., 2010). Errors may also occur in 
measuring doses less than 0.1 ml (Nahata, 1999b). Measuring devices such as syringes and 
needles may be used inappropriately: the dead space in the hub of the syringe and needle 
may contain a large volume in relation to the dose which, if rinsed can introduce a 
substantial error (Leff and Roberts, 1987; Nunn et al., 2013). 
Only liquid preparations for oral use should be administered through small-bore 
nasogastric feeding tubes and if liquid forms are not available, an alternative 
administration route needs to be considered (Engle and Hannawa, 1999; Pagliaro, 2002; 
Dandeles and Lodolce, 2011). When available, it is recommended to use suspensions rather 
than syrups, particularly if the pH of the syrup is very low and it may form clumps with 
enteral nutritional formulas (Williams, 1989). In patients with nasogastric tubes, the taste of 
the product is not relevant. Feeding tubes made of polyurethane seem to have a lower 
incidence of clogging compared to other materials (Pagliaro, 2002). Enteral feeding tubes 
should be flushed with sterile water after every bolus feed and before and after medication 
administration and every four hours if they are providing continuous feeds (Gora, 
Tschampel and Visconti, 1989; Beckwith, Barton and Graves, 1997; Engle and Hannawa, 
1999; Pagliaro, 2002; Dandeles and Lodolce, 2011; BMJ Group, 2012).  
Oral liquid dosage forms should be administered to infants when they are in the same 
position as for breast- or bottle feeding to prevent aspiration of the drug and to prevent the 
drug from running out of the infant’s mouth (Pagliaro, 2002). Infants should be spoken to 
softly, they should be handled gently and should be held and cuddled before and after 
administration. In the newborn, oral liquids may be dispensed via a plastic nipple to take 
advantage of their strong sucking reflex. If the infant refuses the nipple, a plastic oral drug 
syringe can be used. Small amounts of the drug (≤0.5 ml) should be placed between the 
cheek and gum toward the back of the mouth. Subsequently, the infant’s throat can be 
gently stroked outside in a downward motion to facilitate swallowing.  
Administration of an unsuitable formulation to paediatric patients can be stressful, 
traumatic and sub-therapeutic (Tuleu, 2007). Thus, in the present study, appropriate drug 
formulations and dosage forms for different age groups were considered. 
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3 Aims of the Study 
The aim of this study was to evaluate the pharmaceutical properties of hospital pharmacy 
compounded age-appropriate oral dosage forms intended for paediatric patients by using 
nifedipine 1 mg/dose as the model drug. 
 
Specific aims were: 
 
1. to determine the content uniformity of nifedipine in powders and capsules 
prepared from crushed tablets,  
 
2. to determine the chemical stability of nifedipine in powders, 
 
3. to formulate a nifedipine suspension for newborns using hypromellose as an 
excipient and to determine its chemical, microbiological and physical stability, 
and 
 
4. to compare six different nifedipine multi-dose suspensions by evaluating the 
effect of agitation on the content uniformity, and the sedimentation volume.  
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4 Materials and Methods 
4.1 MATERIALS 
4.1.1 Nifedipine (I–V) 
The drug substance, nifedipine (C17-H18-N2-O6; Mol. Wt. 346.3), was obtained either as the 
drug powder (II–III) (Orion Corporation, Turku, Finland) or from manually crushed tablets 
(I–V) (Adalat® 10 mg retard, Bayer AG, Leverkusen, Germany). Crushed nifedipine tablets 
and nifedipine drug powder were scanned with an electron microscope (SEM) (II) (Jeol 
JSM-35 Scanning microscope, Tokyo, Japan).   
According to the manufacturer, the particle size of the nifedipine powder was less than 5 
μm in at least 85% of particles, and all the particles were under 20 μm. The manufacturer 
stated that the particle size of nifedipine in the tablet form was 7–13 μm, with not more than 
20% of particles over 25 μm and at most 2% of the particles over 30 μm.  
Adalat® 10 mg retard can be crushed, because it does not contain any special 
technological structure. The retard effect is based on the particle size and the low water 
solubility of the drug. Adalat® retard tablets contain microcrystalline cellulose and lactose 
as a filler, maize starch as a binder, filler and disintegrant, polysorbate 80 as a wetting agent 
and non-ionic surfactant, and magnesium stearate as a lubricant (Finnish Medicines 
Agency, 2013; Rowe et al., 2012). The filmcoating contains polyethylenglycol (macrogol) 
4000 as a plasticizer in conjunction with film-forming hypromellose, white pigment 
titanium dioxide (E171) as a coating agent, opacifier and colouring pigment, and red 
ferrous oxide (E172) as colouring agent to increase the stability of the light-sensitive active 
ingredient.  
Nifedipine is practically insoluble in water and sensitive to light (European Directorate 
for the Quality of Medicines & Health Care, 2013). In order to prevent photodegradation of 
nifedipine, it was always handled in a dimly lit room, illuminated with a yellow light with 
a wavelength over 450 nm, if needed. 
The photostability of nifedipine is influenced by the wavelength and intensity of light 
exposure, concentration of solution, solvent effects and quality of vials (Thoma and Klimek, 
1985b; Thoma and Klimek, 1991a). When exposed to light, nifedipine undergoes rapid 
photochemical degradation accompanied by a significant reduction in its pharmacological 
activity (Thoma and Klimek, 1985a; Al-Turk et al., 1988; Matsuda, Teraoka and Sugimoto, 
1989; Logan and Patrick, 1990). Although UV-light is very often the cause of the 
degradation of drugs, a distinct spectral region of visible light seems to be responsible for 
most of the photolysis of nifedipine. Thus, nifedipine solution is stable in daylight down to 
a wavelength of 475 nm, but photolysis begins at 450 nm and increases considerably at 
wavelengths around 400 nm. Nifedipine is converted to a nitrosophenylpyridine derivative 
when exposed to daylight and artificial light of certain wavelengths, and to a 
nitrophenylpyridine derivative when exposed to ultraviolet light (Matsuda, Teraoka and 
Sugimoto, 1989; Thoma and Kerker, 1992; Thoma, 1996; European Directorate for the 
Quality of Medicines & Health Care, 2013). 
As many as six photodegradation products have been found when pulverized tablets 
have been exposed to normal room light at room temperature for 30 days while the colour 
of the powder changed from yellow to brown (Hayase et al., 1994). Photodegradation 
products have thought to be inactive but it was reported recently that nitrosonifedipine 
may possess some antioxidant effects (Grundy, Kherani and Foster, 1994; Horinouchi et al., 
2011). 
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4.1.2 Excipients (I–V) 
Lactose (I, IV) (Lactosum monohydricum Ph.Eur. parve granules, Pharmatose® 80 mesh, 
DMV International, Veghel, The Netherlands) was used as filler and diluent in the oral 
solid dosage forms. The bulk density of Pharmatose® 80 mesh is 0.75 mg/cm3 and the 
tapped density is 0.92 mg/cm3 (Rowe et al., 2012). According to the supplier, 70–90% of the 
particles were under 250 μm, <20% were under 100 μm and >95% were under 315 μm.  The 
solubility of lactose in 20°C water is 1 in 5.24 (Rowe et al., 2012).  Lactose is not hygroscopic 
(Allen, 2002). 
Microcrystalline cellulose (IV) (Avicel® PH-102, FMC Corporation or Emcocel® 90M, 
Tamro, Vantaa, Finland) was used as a diluent in the oral solid dosage forms. The bulk 
density for microcrystalline cellulose is 0.29 g/cm3 for Emcocel® 90M and 0.32 g/cm3 for 
Avicel® PH-102 (Rowe, et al., 2012). The tapped densities are 0.35 g/cm3 for Emcocel® 90M 
and 0.48 g/cm3 for Avicel® PH-102 (Doelker et al., 1995; Allen, 2002; Rowe et al., 2012). The 
nominal mean particle sizes are 100 µm and 91 µm for Avicel® PH-102 and Emcocel® 90M, 
respectively, and not more than 8% of the particles are retained in a mesh size of 60 μm and 
at least 45% are retained in a mesh size of 200 μm (Rowe et al., 2012). Microcrystalline 
cellulose is hygroscopic and practically insoluble in water.  
Hypromellose (II, III, V), formerly hydroxypropylmethylcellulose, (Methocel® E50 
Premium LV, Ph.Eur., University Pharmacy, Helsinki, Finland and Hypromellose 50 mPa.s, 
Colorcon, Kent, England) was used as a suspending and thickening agent in liquid 
formulations (Rowe et al., 2012). It has a nominal viscosity of 50 mPa.s for 2% (w/v) aqueous 
solution at 20°C. Hypromellose is practically insoluble in hot water and is soluble in cold 
water forming a viscous colloidal solution. Aqueous solutions may be sterilized by 
autoclaving.  
Methylcellulose (V) (Methylcellulose USP 1500 mPa.s, Sigma-Aldrich, St. Louis, 
Missouri, USA) was used as viscosity-increasing agent in oral suspensions. Methylcellulose 
swells and disperses slowly in cold water, forming a clear to opalescent, viscous, colloidal 
dispersion (Rowe et al., 2012). Cellulose derivatives are liable to microbial spoilage and 
antimicrobial preservatives should be used. 
Sodium benzoate (V) (Ph.Eur., Oriola, Espoo, Finland) was used to preserve 
Methylcellulose 1% vehicle. Sodium benzoate, which is used as preservative in oral 
medicines at concentrations around 0.02–0.5%, dissolves in water 1 in 1.8 and in boiling 
water 1 in 1.4 (Rowe et al., 2012). It has both bacteriostatic and antifungal properties in 
acidic solutions (pH 2–5), but in alkaline solutions it is almost without effect.  
Sucrose (V)  (Ph.Eur., Tamro, Vantaa, Finland) was used as a sweetening and viscosity-
increasing agent to prepare Syrup NF (Rowe et al., 2012). Sucrose is soluble in water at 1 
part in 0.5 parts at 20°C and 1 part in 0.2 parts at 100°C. Dilute sucrose solutions are liable 
to contamination by microorganisms but resist contamination at higher concentrations (e.g. 
above 60% w/w). 
Commercial suspension vehicles (V) Suspension Diluent A® (Nova Laboratories, 
Leicester, UK), SyrSpend SF® Cherry (Gallipot, St. Paul, Minnesota, USA), Ora-Plus® 
(Paddock Laboratories, Minneapolis, Minnesota, USA), Ora-Sweet® (Paddock Laboratories) 
and Ora-Sweet SF® (Paddock Laboratories) were used in the study of multi-dose 
suspensions. 
The excipients used in this study are illustrated in Table 5. 
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Table 5. Excipients of the extemporaneous nifedipine preparations (I–V). All suspensions 
contained purified water (II, III, V). 
 
Dosage 
form 
Vehicle or 
filler 
Suspending 
agents 
Taste 
Flavors 
Preserva-
tives 
Buffers 
Antifoaming 
agents 
pH adjustment 
Oral powder  Lactose - - - - 
Capsule Lactose - - - - 
Capsule Microcrystalline 
cellulose 
- - - - 
Unit-dose 
suspension 
Hypromellose 
1% 
Hypromellose - - - 
Multi-dose 
suspension 
Hypromellose 
1% 
Hypromellose - - - 
Multi-dose 
suspension 
Methylcellulose 
1%–Syrup NF 
Methylcellulose Sucrose 
 
Sodium 
benzoate 
- 
Multi-dose 
suspension 
Suspension 
Diluent A
®
 
Xanthan gum - Methylparaben 
Propylparaben 
- 
Multi-dose 
suspension 
Ora-Plus
®
 Microcrystalline 
cellulose 
Sodium 
carboxymethyl-
cellulose 
Xanthan gum 
Carrageenan 
- Potassium 
sorbate 
Methylparaben 
Sodium 
phosphate 
Citric acid 
Simethicone 
 
Multi-dose 
suspension 
Ora-Sweet
®
 - Sucrose 
Glycerin 
Sorbitol 
Citrus-berry 
Methylparaben 
Potassium 
sorbate 
Citric acid 
Sodium 
phosphate 
 
Multi-dose 
suspension 
Ora-Sweet SF
®
 Xanthan gum 
 
Glycerin 
Sorbitol 
Sodium 
saccharin 
Citrus-berry 
Methylparaben 
Propylparaben 
Potassium 
sorbate 
 
Citric acid 
Sodium citrate 
 
Multi-dose 
suspension 
SyrSpend SF
®
 
Cherry 
Modified food 
starch 
 
Sucralose 
Artificial 
cherry-flavor 
Malic acid 
Sodium 
benzoate 
Sodium citrate 
Citric acid 
Simethicone 
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4.1.3 Packaging materials (I–V) 
Waxed, sealed powder papers (I, IV), which were sized at 47 x 30 mm (Paperityö, Helsinki, 
Finland), were used as the primary package for nifedipine powders.  
Hard gelatin capsules (IV), volumes of 0.50 ml (clear number 1, Tamro, Vantaa, Finland), 
0.30 ml (clear number 3, Gallipot, St. Paul, Minnesota, USA), and 0.21 ml (white number 4, 
Gallipot, St. Paul, Minnesota, USA) were used as the primary package in the capsules, 
whose contents were emptied for use.  
Disposable syringes (II, III) of 2 ml (Discardit®, Becton Dickinson, Madrid, Spain) were 
used as primary packages for unit doses of nifedipine suspensions. The syringes were made 
of polyethylene (PE) and polypropylene (PP). The syringes were capped (Kombi-Stropfen®, 
Clinico, Bad Hersfeld, Germany).   
Black plastic bags (I–IV) (Amerplast, Ikaalinen, Finland) were used as secondary 
packages for all units to protect the nifedipine from light.  
Coloured class bottles of 100 ml (V) (Ardagh Glass, Obernkirchen, Germany) were used 
as the packaging material for multi-dose suspensions.  
4.1.4 Chemicals (I–V) 
Analytical grade nifedipine (N7634, Sigma Chemical Company, St. Louis, MO and N7634, 
Sigma-Aldrich Chemie, Steinheim, Germany) and HPLC-grade methanol (Lab-Scan, 
Dublin, Ireland and Mallinckrodt Baker, Deventer, The Netherlands) were used to prepare 
nifedipine stock solution.  
Bupivacaine hydrochloride (II–IV) (Astra, Finland) was used as an internal standard in 
the HPLC assay of nifedipine. The HPLC’s mobile phase consisted of ammonium acetate (I–
IV), triethylamine (I–IV), acetic acid (I–IV) and phosphate buffer (V) (Phosphoric acid 6024, 
Mallinckrodt Baker). Sodium hydroxide (I, V), hydrochloric acid (I, V) and hydrogen 
peroxide (V) were used in degradation studies. 
Staphylococcus aureus (II–III) (ATCC 25923), Bacteroides fragilis (III) (ATCC 25285) and 
Candica albicans (III) (isolated from clinical specimen) were used for method suitability test 
(II) and for study of antimicrobial properties. Fastidious anaerobe broths (II) (Lab M, UK), 
tryptic soy broths (II) (Difco, USA), sabouraud broths (II) (Oxoid, UK), nutrient agar (III) 
(Oxoid, UK), blood agar (III) (Columbia-agar, BBL, USA, with 5% sheep blood), cled (III) 
(BBL, USA), malassezil (III) (Microbiological laboratory, Kuopio University Hospital) and 
sabouraud (III) (BBL, USA) were used as culture media. 
4.2 METHODS 
4.2.1 Compounding procedures (I–V) 
The following written procedures for compounding were followed: 
 
Nifedipine 1 mg oral powders (I, IV) 
1. Work in a dimly lit room. You may use a yellow light, which has a wavelength of 
over 450 nm. 
2. Place 5 nifedipine 10-mg tablets in a zero-tared metallic mortar. 
3. Grind tablets with a pestle into a fine powder. 
4. By geometric dilution, add the lactose or microcrystalline cellulose to the ground 
tablets to make a sufficient amount of powder. 
5. Mix the resulting powder for 5 minutes. 
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6. Weigh each portion (50 mg, 100 mg, 300 mg or 500 mg) and transfer individually 
to waxed powder papers. 
7. Pack the sealed powder papers in a black plastic bag. 
 
 
Nifedipine 1 mg capsules (IV) 
1. Work in a dimly lit room. You may use a yellow light, which has a wavelength of 
over 450 nm. 
2. Place 5 nifedipine 10-mg tablets in a zero-tared metallic mortar. 
3. Grind tablets with a pestle into a fine powder. 
4. By geometric dilution, add the lactose or microcrystalline cellulose to the ground 
tablets to make a sufficient amount of powder. 
5. Mix the resulting powder for 5 minutes. 
6. Fill the resulting powder into hard gelatin capsules of sizes 1 (0.50 ml), 3 (0.30 ml) 
or 4 (0.21 ml) by using a hand operated capsule filler. 
 
Nifedipine 1 mg/ml oral unit-dose suspension (II, III) 
1. Work in a dimly lit room. You may use a yellow light, which has a wavelength of 
over 450 nm. 
2. Use sterilized equipment under aseptic conditions in a laminar flow hood. 
3. Count out 5 nifedipine 10-mg tablets, or measure the required amount of 
nifedipine drug powder. 
4. Measure out 50 ml of hypromellose 1% m/v vehicle. 
5. Put the tablets and a small amount of hypromellose 10 mg/ml in a mortar (not 
ceramic because of porosity) and allow soaking for 5 min. The filmcoating of the 
tablet will dissolve in the liquid. 
6. Crush the tablets and mix to a uniform paste with the mortar and pestle. 
7. Add geometric amounts of vehicle to the desired volume while mixing. 
8. Draw the required amount of suspension into a single unit (oral) syringe and 
close the syringe with the cap. Mix the suspension. Draw as many syringes as 
needed. 
9. Label the syringe for peroral use with a note to shake well before using. Never use 
a needle, in order to reduce the possibility of medication error. 
10. Put the syringe into a black plastic bag for storage; this will protect the nifedipine 
from light. Label the plastic bag. 
11. Before administration, draw a little amount of air into the syringe and resuspend 
the solid sedimented particles by shaking. 
 
Nifedipine 1 mg/ml oral suspension 100 ml (V) 
1. Work in a dimly lit room. You may use a yellow light, which has a wavelength of 
over 450 nm. 
2. Use sterilized equipment under aseptic conditions in a laminar flow hood. 
3. Count out 7 nifedipine 10-mg tablets. 
4. Grind the tablets with a pestle in a stainless steel (or melamine) mortar to a 
uniform fine powder. 
5. Suspend the powder with 2 ml of suspension vehicle.  
6. Add suspension vehicle via geometric dilution to the volume of 70 ml while 
mixing.   
7. Store in a coloured 100 ml glass bottle. 
8. Label the bottle ‚Shake well before use‛. 
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Hypromellose 1% m/v vehicle 1000 ml (II, III, V) 
1. Measure 10.0 g hypromellose 50 mPa.s into a bottle of sufficient size to 
accommodate the total volume of the required solution. 
2. Place one-third of the total water volume in a container, and heat to 80–90 °C with 
vigorous stirring until agglomerates disappear and particles are thoroughly 
wetted. 
3. Add cold water (≈ 5 °C) to a volume of 1000 ml. Continue stirring gently until the 
mixture is homogenous. 
4. Allow the solution to cool in ice-cold water until thoroughly hydrated, and then 
allow it to gradually warm to ambient temperature. 
5. Divide the solution into usable portions, as in vials, which may then be sterilized 
by autoclave. 
6. Autoclave at 121 °C for 20 min. 
7. Allow cooling to room temperature. 
 
Methylcellulose 1% m/v solution H.S.C. 100g (V) (Rappaport, 1983) 
1. Dissolve 0.2 g sodium benzoate in 20 ml of boiling distilled water. 
2. Add 1.0 g methylcellulose 1500 mPa.s powder and stir well in a blender for 2–3 
minutes. 
3. Add 80 ml ice-cold water (cautiously but quickly) and stir or blend well for 5–10 
minutes.  
4. Transfer to a 100 ml bottle. 
5. Refrigerate for at least 4 hours until the creamy thick white liquid is converted to a 
clear gel. Mix contents occasionally by rolling gently. 
 
Syrup NF (Simple Syrup) 100 ml (V) (de Villiers, 2009b) 
1. Weigh 85 g sucrose and a sufficient quantity of purified water to make 100 ml of 
solution. 
2. Heat up until the sucrose dissolves. 
3. Store in a 100 ml glass bottle. 
 
Suspension Vehicle H.S.C. (Methylcellulose 1%/Syrup NF) 100 ml (V) (Rappaport, 1983) 
1. Add 70 ml of Methylcellulose 1% H.S.C. in 30 ml of Syrup NF. 
2. Stir well using a rod or blender if available. The liquid foams easily. 
3. Store in a 100 ml glass bottle. 
4. Mix by rolling gently. 
5. Store at room temperature overnight or for a minimum of 4 hours before use. 
4.2.2 High performance liquid chromatography (I–V) 
Nifedipine amount was measured in studies I–V by a reproducible and validated stability-
indicating HPLC method (Mehta, 1993; Hagan, 1994; ICH Harmonised Tripartite Guideline, 
2012). A forced photodegradation experiment on the nifedipine compound was performed 
in order to verify the stability-indicating capability of the HPLC method (Anderson, 1996). 
Specificity was evaluated by exposing nifedipine drug powder and crushed nifedipine 10 
mg tablet to wavelengths of visible and UV-light until significant degradation occurred (I, 
II). In a preliminary study, nifedipine powder papers were removed from their outer carton 
and left on a windowsill for six days. In study V, nifedipine sample suspensions were 
exposed to window light for 1 hour. All suspensions were also allowed to stand at room 
temperature and protected from light for 1 month. 
Specificity was verified by heating 1 ml of nifedipine standard solution 1 mg/ml and a 
crushed nifedipine 10 mg tablet, which were first mixed with either 1 M hydrochloric acid 
or 1 M sodium hydroxide to a volume of 10 ml (II). The solutions were heated at 60°C for 2 
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days. Both the nifedipine drug powder and crushed tablet were heated at 120°C for 2 hours. 
In study V, all nifedipine sample suspensions were treated with either sodium hydroxide, 
hydrochloric acid and hydrogen peroxide, and heated in a water bath at 70°C. The 
chromatograms of the nifedipine standard were compared to the degraded sample in order 
to ensure that no interfering peaks exist. The identity of nifedipine was also confirmed by 
liquid chromatography-mass spectrometry (I). 
The system precision of the HPLC method was examined with 10–15 injections of 
nifedipine standard solutions in intra-day and interday variation assays (I–IV). In study V, 
the system suitability, inter-day and intra-day variations were assayed by six injections 
from six samples per day during three days. The correlation coefficients were determined 
in all studies to assure linearity.  
The concentrations of nifedipine formulations were estimated by peak height (I) or area 
(II–V) relative to the drug substance using HPLC with UV detection at a wavelength of 238 
nm (I–V) and 332 nm (V). The HPLC system used in each of the studies has been described 
in publications I, II, IV and V with a reversed phase C18 column being used. The mobile 
phase consisted of 68–70% methanol in 30–32% deionized distilled water which contained 
0.1M ammonium acetate and 0.1% triethylamine (I–IV). The pH was adjusted to 5.8. The 
flow rate was 1.0 ml/min. Bupivacaine was used as an internal standard (II, III, IV).  In 
study V, the mobile phase consisted of 60% methanol in 40% phosphate buffer (30 mM, pH 
7.0). The column temperature was maintained at 35°C and the mobile phase flow rate at 0.8 
ml/min. 
Each randomly selected 1 mg sample of nifedipine oral powder, capsule or suspension 
was emptied carefully into a sample bottle. Methanol was added to a total volume of 10.0 
ml. Ultrasound sonication (I, IV), centrifuging (II, III), shaking (IV) and vortex mixer 
followed by blending by hand once an hour for 3 hours (V) were used to ensure dissolution 
of nifedipine.  
In order to prepare a sample solution, a 1000 µl of the resulting nifedipine solution was 
diluted 1:10 with methanol (I–IV) or a 500-µl sample was taken (V). This solution as such (I, 
V) was assayed by HPLC, or a 750-μl aliquot of solution was mixed with 250 μl of 
bupivacaine solution, which acted as an internal standard (II–IV) prior to HPLC analysis. 
All the samples were prepared in a dimly lit room (I–IV) or in a dark room illuminated with 
a yellow light with a wavelength over 450 nm (V) and then protected from light. 
4.2.3 Uniformity of dosage units (I, II, IV, V) 
The content uniformities of the nifedipine oral powders (I, IV), capsules (IV) and 
suspensions (II, V) were determined by methods described in the European Pharmacopoeia 
(Council of Europe, 1996; Council of Europe, 2006; Council of Europe, 2008). Nifedipine 
oral powders and unit-dose suspensions were studied immediately after preparation (I, II, 
IV). The content uniformity of multidose suspensions was tested after preparation and after 
1, 2 and 4 weeks of storage at room temperature (23±2°C) protected from light (V). At each 
time point, the sample bottle was mixed either by inverting the bottle 10–15 times or only 3 
times to mimic the shaking likely to take place in daily practice. 
The test for content uniformity is based on the assay of the individual contents of active 
substance of a number of dosage units to determine whether the individual contents are 
within the set limits. Ten dosage units were taken at random and individual contents of 
nifedipine were determined using HPLC.  
Nifedipine oral powders, capsules and single-dose suspensions complied with the test 
Uniformity of content of single-dose preparations (2.9.6) if not more than one of the 10 
individual contents was outside the limits of ±15% of the average content, and if none were 
outside the limits of ±25% of the average content (I, II, IV) (Council of Europe, 1996; Council 
of Europe, 2006).  
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Nifedipine multidose suspensions complied with the test Uniformity of dosage units 
(2.9.40) if the Acceptance value (AV) of the first 10 dosage units is at maximum 15.0 
(Council of Europe, 2008). This new formula takes into account the target content of the 
product. The AV was calculated by using the formula: 
 
  |M − |+ ks     (2) 
where reference value (M) is defined by the mean of the individual contents ( ) expressed 
as a percentage of the label claim, when the target content (T) is ≤ 101.5. The k is the 
acceptability constant, which is 2.4 for ten samples, and s is the sample standard deviation. 
4.2.4 Uniformity of mass (V) 
Uniformity of mass of delivered doses from multidose containers (2.9.27) was investigated 
by using the method described in the European Pharmacopoeia (V) (Council of Europe, 
2008). Twenty samples were taken from the freshly prepared and inverted nifedipine 
suspensions and weighed individually. The suspension complied with the test if not more 
than two of the 20 individual masses deviated from the average mass by more than 10% 
and none deviated by more than 20%. 
4.2.5 Hypromellose concentration (II) 
To find the optimal resuspendible and dose-accurate combination, different concentrations 
of hypromellose colloids were compounded with both nifedipine drug powder and 
crushed tablets and doses of 50 ml were packaged in clear glass vials, which were stored at 
room temperature protected from light (II).  
Hypromellose powder was wetted with hot (80–90°C) water and cold (5°C) water was 
then added and the hypromellose solution was allowed to cool in ice-cold water until it was 
thoroughly hydrated. Hypromellose solution was sterilized in an autoclave. The 
hypromellose concentrations of 0%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5% and 3.0% were used. 
The following tests were applied to the nifedipine suspensions compounded with 
different hypromellose vehicles: 
 visual observation of sedimentation after one month of storage at room 
temperature (22–23°C, relative humidity (RH) of 60–72%), 
 measurement of the nifedipine concentration from the upper, middle and lower 
parts of the suspension vial 15 seconds after redispersion of the sediment by 
inverting the vial 10 times, 
 measurement of the nifedipine concentration from the middle part of the vial 
immediately, 1 min and 2 min after shaking, and 
 measurement of the nifedipine concentration and evaluating its resuspending 
properties after one month of storage in a unit dose syringe at room temperature 
(22–23°C, 60–72% RH). 
4.2.6 Chemical stability studies (I, III) 
In the tests of stability, the samples were stored under three controlled conditions: 1) at 
room temperature (21–23°C, 43–47% RH (I), 60–72% RH (III)) protected from light, 2) in a 
refrigerator (5–7°C, 60–66% RH (I), 67–77% RH (III)) protected from light, and 3) at room 
temperature (21–23°C, 60–72%RH (I), 58–62% RH (III)) exposed to artificial daylight in 
primary packaging material (400 lux at a distance of 60 cm from the fluorescent lamp) (TLD 
36W/965, natural daylight 6500, Philips, Roosendaal, Holland) or to natural daylight. The 
temperatures of the room and refrigerator were adjusted according to the European 
Pharmacopoeia (Council of Europe, 1996; Council of Europe, 2006).  
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If one wishes to test photostability of a drug product, it is desirable to use a greater 
exposure to light than is likely to occur under practical conditions (Anderson et al. 1991). 
‘Artificial daylight’ fluorescent tubes simulating glass-filtered daylight were used in studies 
I and III. The spectral distribution of the light sources used was determined (III). The 
illumination of the sample area was measured with a lux meter (I, III). 
When being exposed to light, solid drug substances were spread across the folded 
powder paper. The samples from the powder papers and oral syringes were spread in a 
single layer to provide a maximum area of exposure to the light source.  
Nifedipine powder papers were stored for either 12 months protected from light or for 5 
days when exposed to light (I). Nifedipine suspensions made in the optimal vehicle, 
hypromellose 1%, were stored for 28 days protected from light or for 7 days when exposed 
to artificial daylight (III). 
Samples were removed after the pre-determined period of storage and were analysed by 
HPLC to assay the nifedipine concentration and to assess the degree of photodegradation. 
Drugs were considered stable if they retained ≥ 90% of the initial drug concentration. 
4.2.7 Physical stability studies (II, III, V) 
Both nifedipine 1 mg/ml suspension and the optimal vehicle, hypromellose 1.0% solution, 
were tested for density (Mohr Westphal® scale, Germany), pH (Mettler® Toledo 320, 
Switzerland), osmolality (Osmostat® Auto-Osmometer, Japan), viscosity (Falling Sphere 
Viscometer® and Haake Rotovisco® RV 2, Gebrüder Haake®, Germany), surface tension 
(Krüss Interfacial Tensiometer®, GWB, Germany) and organoleptic properties (II, III).  
Nifedipine suspensions were tested immediately after preparation and on days 14 and 28 
of storage at either room temperature (22°C, 60–72% RH) or being kept in a refrigerator 
(6°C, 67–77% RH) (III). Hypromellose 1.0% solution was studied at 20°C at the time of 
preparation, before and after steam sterilization and then at 3, 6 and 12 months (II). All 
equipment was calibrated at regular intervals as recommended by the manufacturers. 
The sedimentation volume of the nifedipine suspensions was observed visually over 4 
weeks (V). Suspensions were stored in cylindrical graduated flasks in the dark at room 
temperature (22±2°C) so that the settled powder sediment on the bottom and the clear 
supernatant phase on the top of the suspension could be easily observed. 
4.2.8 Microbiological stability studies (II, III, V) 
Although the European Pharmacopoeia does not require that an oral preparation should be 
microbe-free, this is, of course, preferable for critically ill neonates (European Directorate 
for the Quality of Medicines & Health Care, 2013). According to the European 
Pharmacopoeia, the acceptance criteria for non-sterile aqueous preparations for oral use are 
total aerobic microbial count of 102 CFU/ml (maximum acceptable count is 200) and total 
combined yeasts/molds count of 101 CFU/ml (maximum acceptable count is 20) and the 
complete abcence of Escherichia coli. 
The microbiological stability of nifedipine suspensions and hypromellose 1.0% solution 
were investigated by using the European Pharmacopoeia method (II, III) (Council of 
Europe, 1998). The antimicrobial properties of the nifedipine solution were studied.  
The microbiological quality of nifedipine suspensions was determined immediately after 
preparation and on days 7, 14, 21 and 28 days after storage began either protected from 
light at room temperature (22°C, 60–72% RH) or in a refrigerator (6°C, 67–77% RH). 
 The sterility of the hypromellose 1.0% solution was tested after steam sterilization, and 
after 3, 6 and 12 months of storage at room temperature (22°C, 60–72% RH) using the 
method of direct inoculation (Council of Europe, 1998). Fastidious anaerobe broths, tryptic 
soy broths and sabouraud broths were used as culture media. Inspection of cultures was 
conducted after 14 days of incubation at 22°C and 35°C. 
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The microbiological quality of the nifedipine multi-dose suspensions (V) was studied 
preliminary by inoculating 0.5-ml sample of the suspension to the blood agar and nutrient 
agar both after the preparation and at the end of the 1-month storage period. The agars 
were incubated at 35°C for 2 days and then at 22°C for 3 days. 
 
40 
 
 
5 Results 
5.1 MORPHOLOGY OF NIFEDIPINE POWDER AND CRUSHED TABLETS 
The morphologies of nifedipine drug powder and crushed Adalat® 10 mg retard tablets 
were characterized in SEM (II). Crushing of nifedipine tablets produced particles that 
differed in size and shape whereas nifedipine drug powder was relatively uniform (Figures 
2–4).  
 
 Figure 2. Nifedipine tablet crushed manually with a mortar and pestle and examined in a SEM. 
Scale bar is 100 μm. (I–V) 
 
Figure 3. Nifedipine tablet crushed with an electronic crusher (Bamix®) for about 1 minute and 
examined in a SEM (unpublished data). Scale bar is 100 μm. 
 
Figure 4. Nifedipine drug powder as viewed in a SEM. Scale bar is 100 μm. (II, III) 
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5.2 UNIFORMITY OF DOSAGE UNITS AND UNIFORMITY OF MASS (I, II, IV, V) 
The content uniformities of nifedipine oral powders (I, IV), capsules (IV) and unit-dose 
suspensions (II) complied with the test specifications although some loss of nifedipine was 
observed (Table 6). The maximum deviations of the 10 individual contents were below 
±15% of the average content (Table 7). No major differences in content uniformity were 
noted between hypromellose concentrations 0.5%, 1.0% and 1.5% or between nifedipine 
drug powders and crushed tablets in nifedipine suspensions that were packaged in vial. 
A comparison between the different amounts of lactose and microcrystalline cellulose as 
excipients in nifedipine 1 mg oral powders of 500 mg and 300 mg and capsules of sizes 1, 3 
and 4 indicated that content uniformity remained acceptable in both cases although the 
content was reduced to about 85–90% of the theoretical value (Table 7) (IV). In nifedipine 1 
mg powders weighing 100 mg and 50 mg, the content was below 80% of the theoretical 
value both with lactose and microcrystalline cellulose (Figures 5 and 6). The nifedipine 
content was over 80% of the theoretical value in small capsules where the amount of the 
excipients were quite similar. Thus, 80 mg of microcrystalline cellulose or 160 mg of lactose 
was sufficient when compounding capsules. Instead, the amount of excipient in oral 
powders would need to be higher, since the amount of recovered nifedipine decreased as 
the total mass decreased. Nifedipine recovery was nearly the same in all emptied capsules 
compared with emptied oral powders weighing 300 mg or more. 
It was noted that about 8% of the nifedipine amount of 1.0 mg was lost during the 
preparation and storage of powder papers and about 75% of that was identified to be 
present on the emptied powder papers (Table 6)(I). Minor amounts were found in the 
mortar and pestle and the other equipment used.  
The multidose suspensions compounded with six different suspension vehicles complied 
with the test at each time point (AV≤15) when the suspension was mixed by inverting the 
bottle 10–15 times (Table 7)(V). Instead, when the suspension bottles were inverted only 
three times before sampling, the nifedipine suspensions compounded either with 
Methylcellulose 1%/Syrup NF or Hypromellose 1% vehicle did not comply with the test 
after 1 week of storage at room temperature while protected from light (Tables 8–10). In 
contrast, the four commercial suspensions complied with the test at each time point, even 
when they were mixed only by inverting the bottles three times. 
The uniformity of mass of all freshly compounded nifedipine suspensions complied with 
the test specified in the European Pharmacopoeia (Table 11) (V). 
 
 
Table 6. Loss of nifedipine during compounding process of 50 nifedipine 1.0 mg oral powders 
(n=1) (unpublished data). 
 
Material Amount of nifedipine (mg) 
Total content of 50 oral powders 46 
Mortar 0.5 
Pestle 0.2 
Tablet crusher 0.2 
Other equipment (spatula, spoon etc.) 0.1 
Emptied 50 powder papers 3.0 
Total amount of nifedipine 50 
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Table 7. Content uniformities of nifedipine 1.0 mg in oral powders (I, IV), capsules (IV), unit-
dose suspensions (II) and multidose suspensions (V) measured immediately after preparation 
complied with the requirements of European Pharmacopoeia (unpublished data of multi-dose 
suspensions).  
 
Product Nifedipine* Excipient Mean SD (mg) Maximum 
deviation 
from the 
mean(%) 
Oral powders 500 mg  Crushed tablet Lactose  0.92 ± 0.03 (I) 
0.87 ± 0.02 (IV) 
+4.6 (I) 
+3.3 (IV) 
Oral powders 500 mg  Crushed tablet Cellulose microcrystalline  0.91 ± 0.04 -8.0 
Oral powders 300 mg  Crushed tablet Lactose  0.85 ± 0.03 +6.7 
Oral powders 300 mg  Crushed tablet Cellulose microcrystalline 0.88 ± 0.02 +2.6 
Oral powders 100 mg  Crushed tablet Lactose  0.77 ± 0.05 +14.9 
Oral powders 100 mg  Crushed tablet Cellulose microcrystalline 0.70 ± 0.03 +7.3 
Oral powders 50 mg  Crushed tablet Lactose  0.71 ± 0.04 -13.4 
Oral powders 50 mg  Crushed tablet Cellulose microcrystalline 0.62 ± 0.02 -5.9 
Capsules n:o 1 Crushed tablet Lactose  0.85 ± 0.02 +8.4 
Capsules n:o 1 Crushed tablet Cellulose microcrystalline 0.86 ± 0.04 +10.6 
Capsules n:o 3 Crushed tablet Lactose  0.87 ± 0.02 +3.8 
Capsules n:o 3 Crushed tablet Cellulose microcrystalline 0.83 ± 0.03 +5.8 
Capsules n:o 4 Crushed tablet Lactose  0.87 ± 0.01 -3.1 
Capsules n:o 4 Crushed tablet Cellulose microcrystalline 0.83 ± 0.05 -10.9 
Unit-dose suspension Crushed tablet Hypromellose 1% 1.06 ± 0.05 +8.5 
Unit-dose suspension Crushed tablet Hypromellose 1.5% 1.06 ± 0.04 +5.7 
Unit-dose suspension Drug powder Hypromellose 0.5% 1.07 ± 0.05 +6.5 
Unit-dose suspension Drug powder Hypromellose 1% 1.09 ± 0.05 +9.2 
Multi-dose suspension Crushed tablet Suspension Diluent A
®
 0.99 ± 0.02 -3.5 
Multi-dose suspension Crushed tablet Ora-Plus
®
/Ora-Sweet
®
 1.04 ± 0.01 +5.2 
Multi-dose suspension Crushed tablet Ora-Plus
®
/Ora-Sweet SF
®
 0.94 ± 0.01 -8.4 
Multi-dose suspension Crushed tablet SyrSpend SF
®
 Cherry 0.99 ± 0.01 -2.7 
Multi-dose suspension Crushed tablet Methylcellulose 
1%/Syrup NF 
0.93 ± 0.09 -15.6 
Multi-dose suspension Crushed tablet Hypromellose 1% 1.00 ± 0.02 +3.7 
*Crushed tablet is Adalat® 10 mg retard (Bayer AG) 
43 
 
 
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
1,00
50
oral powder
100
oral powder
160
capsule
230
capsule
300
oral powder
400
capsule
500
oral powder
total weight (mg)
n
if
e
d
ip
in
e
 (
m
g
)
 
Figure 5. Nifedipine content in oral powders and emptied capsules number 1 (400 mg), 3 (230 
mg) and 4 (160 mg) filled with lactose (IV). Theoretical amount of nifedipine was 1 mg. Mean 
values are shown (n = 10). 
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Figure 6. Nifedipine content in oral powders and emptied capsules number 1 (200 mg), 3 (130 
mg) and 4 (80 mg) filled with cellulose microcrystalline (IV). Theoretical amount of nifedipine 
was 1 mg. Mean values are shown (n = 10). 
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Table 8. The uniformity of dosage units of nifedipine 1 mg/ml oral suspensions compounded 
with the six different vehicles and mixed by inverting the bottles either 10–15 times or 3 times 
before sampling (V). Suspensions were stored at room temperature. The preparation complies 
with the test if the AV is at maximum 15.0. 
 
Suspension vehicle Acceptance value ± standard deviation (AV±SD, n=10) 
Mixing protocol Initial 1 week 2 weeks 4 weeks 
Suspension Diluent A
®
     
10–15 times 0.04 ± 0.02 3.61 ± 0.02 1.19 ± 0.01 3.71 ± 0.03 
3 times 2.18 ± 0.01 3.85 ± 0.04 0.05 ± 0.02 1.67 ± 0.02 
Ora-Plus
®
/Ora-Sweet
®
     
10–15 times 2.61 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
3 times 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 0.76 ± 0.01 
Ora-Plus
®
/Ora-Sweet SF
®
     
10–15 times 4.85 ± 0.01 3.74 ± 0.02 1.41 ± 0.01 5.90 ± 0.01 
3 times 0.01 ± 0.01 0.03 ± 0.01 2.03 ± 0.01 1.06 ± 0.01 
SyrSpend SF
®
 Cherry     
10–15 times 0.03 ± 0.01 4.39 ± 0.03 1.77 ± 0.01 3.57 ± 0.01 
3 times 0.74 ± 0.01 1.76 ± 0.02 0.04 ± 0.02 0.70 ± 0.01 
Methylcellulose 
1%/Syrup NF 
    
10–15 times 5.31 ± 0.09 0.03 ± 0.01 1.09 ± 0.01 1.02 ± 0.02 
3 times 2.58 ± 0.02 70.52 ± 0.04 - - 
3 times 18.41* ± 0.22 69.92 ± 0.00 - - 
Hypromellose 1%     
10–15 times 0.05 ± 0.02 2.69 ± 0.02 1.23 ± 0.07 0.03 ± 0.01 
3 times 0.32 ± 0.03 26.27 ± 0.08 - - 
3 times 1.04 ± 0.01 21.86 ± 0.15 - - 
*exception to study protocol (AV>15), one week measurement was done to confirm the result 
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Table 9. The measured concentration of nifedipine in Methylcellulose 1%/Syrup NF -suspension 
mixed by inverting the bottle three times initially and after one week of storage at room 
temperature protected from light, the deviation from the theoretical concentration (1 mg/ml) 
and the calculated acceptance value (AV) (V). The preparation complies with the test if the AV 
is at maximum 15.0. 
 
 Sample  Initial 1 week Initial 1 week 
 
Conc.  
(mg/ml) 
Deviation 
(%) 
Conc.  
(mg/ml) 
Deviation 
(%) 
Conc. 
 (mg/ml) 
Deviation 
( %) 
Conc. 
(mg/ml) 
Deviation 
(%) 
1 0.95 -4.87 0.26 -73.56 0.65 -35.03  0.29 -71.44 
2 0.94 -5.99 0.25 -74.88 0.65 -35.38  0.29 -70.98 
3 0.96 -3.65 0.25 -74.84 0.64 -35.97  0.29 -70.99 
4 0.93 -7.23 0.25 -75.12 0.64 -36.21  0.28 -71.52 
5 0.95 -4.85 0.25 -74.63 0.67 -33.25  0.29 -71.49 
6 0.95 -4.69 0.28 -72.48 0.68 -32.12  0.29 -71.48 
7 0.99 -1.37 0.27 -72.50 0.82 -18.16  0.28 -71.53 
8 0.98 -2.03 0.28 -71.83 1.02 1.94  0.28 -72.19 
9 0.99 -0.60 0.33 -67.11 1.17 16.51  0.29 -71.33 
10 0.95 -5.01 0.38 -62.24 1.14 13.78  0.29 -71.17 
 (mg/ml) 0.96  0.28  0.81  0.29  
SD 0.02  0.04  0.22  0.00  
 (%) 95.97   28.08   80.61   28.59   
AV 2.58   70.52   18.41   69.92   
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Table 10. The measured concentration of nifedipine in Hypromellose 1% -suspension mixed by 
inverting the bottle three times initially and after one week of storage at room temperature 
protected from light, the deviation from the theoretical concentration (1 mg/ml) and the 
calculated acceptance value (AV) (V). The preparation complies with the test if the AV is at 
maximum 15.0. 
 
  Initial 1 week Initial 1 week 
 Sample 
Conc.  
(mg/ml) 
Deviation 
(%) 
Conc.  
(mg/ml) 
Deviation 
(%) 
Conc.  
(mg/ml) 
Deviation 
(%) 
Conc.  
(mg/ml) 
Deviation 
(%) 
1 1.01 1.47 0.91 -9.24 1.00 -0.14 0.52 -48.21 
2 0.98 -1.80 0.67 -32.90 0.97 -3.02 0.60 -39.88 
3 0.97 -3.35 0.67 -33.43 0.98 -1.76 0.63 -37.18 
4 1.03 3.39 0.66 -33.78 0.97 -3.13 0.74 -25.94 
5 0.97 -3.35 0.68 -31.82 0.97 -3.20 0.76 -23.79 
6 0.95 -5.48 0.66 -34.32 0.97 -2.87 0.81 -18.73 
7 0.96 -3.83 0.71 -28.79 0.97 -2.68 0.86 -14.02 
8 0.98 -2.28 0.75 -24.72 0.97 -3.12 0.85 -14.84 
9 0.98 -1.83 0.81 -18.79 0.97 -3.03 0.96 -4.38 
10 1.00 -0.44 0.72 -28.01 0.98 -2.21 0.97 -3.00 
 (mg/ml) 0.98  0.72  0.97  0.77  
SD 0.03  0.08  0.01  0.15  
 (%) 98.25   72.42   97.48   77.00   
AV 0.32   26.27   1.04   21.86   
 
 
Table 11. Uniformity of mass and maximum deviation from the mean of the mass of nifedipine 1 
mg/ml suspensions in six different suspension vehicles (unpublished data). 
 
Uniformity 
of mass 
Suspension 
Diluent A
®
 
OraPlus
®
/Ora-
Sweet
®
 
OraPlus
®
/Ora-
Sweet 
SF
®
 
SyrSpend 
SF
®
 Cherry 
Methylcellulose 
1%/Syrup NF 
Hypromellose 
1% 
Mean 
(mg)* 
982.41 1172.98 1020.47 1011.80 1088.29 1005.18 
Maximum 
deviation 
(%) 
-1.2 ±1.4 -9.8 -10.4 +1.5 -12.7 
* Mean of twenty 1.0 ml samples 
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5.3 HYPROMELLOSE CONCENTRATION (II) 
Nifedipine suspensions that were made from hypromellose concentrations of 0.5%, 1.0% 
and 1.5% were easier to redisperse than the other suspensions, which had hypromellose 
concentrations of 0%, 2.0%, 2.5% or 3.0% (Table 12) (II). No significant differences in the 
nifedipine concentrations were observed at hypromellose suspensions of 0.5, 1.0 and 1.5% 
measured immediately, 1 min and 2 min after shaking the vial. The suspensions made from 
nifedipine drug powder were more difficult to redisperse than the suspensions made from 
crushed nifedipine tablets, but the concentrations after mixing were close to each other. As 
a result, hypromellose 1.0% was selected as a vehicle for use in further suspensions with 
both drug powders and crushed tablets. 
 
Table 12. Nifedipine 1 mg/ml suspension concentration measured from upper, middle and lower 
part of the vial 15 seconds after shaking (II). 
 
Hypromellose 
concentration 
(%) 
Nifedipine* Nifedipine concentration (mg/ml) 
  Upper Middle Lower Mean±RSD 
0 Crushed tablet 0.79 0.70 0.68 0.72 ± 0.06a 
0.5 Crushed tablet 0.94 0.88 0.91  0.91± 0.03a 
1.0 Crushed tablet 0.99 1.00 1.04 1.01 ± 0.03a 
1.5 Crushed tablet 0.98 0.91 0.81 0.90 ± 0.09a 
2.0 Crushed tablet 0.76 0.75 0.83 0.78 ± 0.04a 
2.5 Crushed tablet 0.80 0.80 0.80 0.79 ± 0.01a 
3.0 Crushed tablet 0.67 0.80 0.84 0.77 ± 0.09a 
0 Drug powder 0.69 0.76 0.61  0.69 ± 0.08b 
0.5 Drug powder 1.04 1.07 1.06 1.06 ± 0.02b 
1.0 Drug powder 0.96 0.92 0.88 0.92 ± 0.04b 
1.5 Drug powder 1.00 1.02 0.99 1.00 ± 0.02b 
2.0 Drug powder 1.02 1.04 0.99 1.02 ± 0.03b 
2.5 Drug powder 0.97 1.00 1.00 0.99 ± 0.02b 
3.0 Drug powder 0.81 0.99 1.09 0.96 ± 0.14b 
*Crushed tablet is Adalat® 10 mg retard (Bayer AG) 
aReported as mean concentration of duplicate determinations for two samples. 
bReported as mean concentration of duplicate determinations for four samples. 
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5.4 CHEMICAL STABILITY OF NIFEDIPINE (I, III) 
At least 94% of the initial concentration of nifedipine remained in the powders that were 
protected from light and stored at room temperature or kept in a refrigerator for one year 
(Table 13) (I). In the suspensions compounded from crushed tablets 95% of the mean 
nifedipine concentrations remained, and from drug powder the corresponding value was 
93% in the suspensions stored at room temperature protected from light, throughout the 28-
day study period (Table 14) (III). When stored in a refrigerator protected from light, the 
corresponding values were 91% and 92% remaining. No evidence for the presence of 
degradation products was observed in the HPLC assay. 
Significant degradation of nifedipine was observed in the powders and suspensions 
exposed to artificial daylight (Table 15) or natural daylight through a window (Figure 7). 
The spectrum of artificial full colour daylight resembled the spectrum of mixed artificial 
light of the room and natural daylight coming through a window (I, III) (Figures 8–9). The 
illumination of the sample area was found to be 400 lux at a distance of 60 cm from the 
lamp. 
 Photodegradation of the nifedipine exceeded 20% within three hours and 40% within six 
hours and was essentially complete after three days (Table 15). In suspensions made from 
crushed tablets, photodegradation exceeded 26% within three hours and 40% within six 
hours, and was essentially complete after 7 days. Nifedipine powder in suspensions 
degraded more rapidly: 30% within three hours and nearly the entire active drug has 
disappeared after three days. The photodegradation products of nifedipine were not 
specified in these studies but mainly one photodegradation product seemed to be present 
based on the mass spectrometry analysis (unpublished data). 
 
Table 13. Chemical stability of nifedipine 1mg oral powders, stored at room temperature (22°C) 
and in a refrigerator (6°C) protected from light (I). 
 
 % Initial nifedipine concentration remaininga 
Storage Time At room temperatureb In refregeratorc 
7 days 105.6  6.3  104.5  5.4 
14 days 103.7  7.2 94.3  5.5 
21 days 100.7  6.3 103.9  3.5 
28 days 102.1  5.1 103.7  5.6 
2 months 108.5  4.0 97.8  5.8 
3 months 104.2  5.9 97.5  2.9 
4 months 110.1  4.2 102.3  5.1 
6 months 101.5  2.7 109.3  4.7 
8 months 103.4  2.4 101.4  3.3 
10 months 96.2  3.1 96.5  4.8 
1 year 98.2  1.8 101.6  4.1 
aReported as mean-% SD of triplicate determinations for six samples. 
bInitial nifedipine concentrations per dose were 0.93 0.05 mg, 0.96 0.05 mg and 0.94 0.05 mg. 
cInitial nifedipine concentrations per dose were 0.93 0.05 mg, 0.95 0.04 mg and 0.91 0.05 mg. 
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Table 14. Chemical stability of nifedipine 1 mg unit-dose suspensions compounded both with 
crushed tablets or drug powder, stored either at room temperature (22–23°C) or in a 
refrigerator (5–7°C) and protected from light (III). 
 
 % Initial nifedipine concentration remaininga 
Storage Time At room temperature In refrigerator 
 Tablet*b Powderc Tablet*d Powdere 
1 days 95.3  5.9 93.0  6.6 98.6  3.8 92.2  3.9 
3 days 102.6  5.1 94.4  7.0 102.5  1.6 96.2  3.4 
5 days 104.0  3.5 96.7  2.5 99.3  6.2 95.6  7.4 
7 days 104.1  8.6 95.2  1.9 104.3  4.9 94.0  4.7 
14 days 107.8  4.9 104.1  6.6 103.9  3.1 103.9  4.8 
21 days 94.9  6.4 96.4  2.5 95.2  2.1 93.6  3.0 
28 days 99.1  6.8 95.0  4.7 90.7  6.0 92.0  5.2 
*Crushed tablet is Adalat® 10 mg retard (Bayer AG) 
aReported as mean-% SD of duplicate determinations for six samples. Initial nifedipine concentrations per 
dose were b0.95 0.05 mg, c1.00 0.05 mg, d0.96 0.02 mg and e1.03 0.02 mg in 1 ml of suspension. 
 
 
Table 15. Chemical stability of nifedipine 1 mg oral powders and nifedipine 1 mg/ml unit-dose 
suspensions, compounded either with crushed tablets or drug powder, stored at room 
temperature (21–23°C) exposed to artificial daylight (unpublished data of oral powders). 
 
 % Initial nifedipine concentration remaining  
Storage Time Oral powder a Unit-dose suspension b 
 Tablet* Tablet* c Powder d 
3 hours 77.9  4.6 73.5  5.6 68.8  11.3 
6 hours 56.2  1.3 57.0  4.8 46.3  9.7 
18 hours 20.5  2.0 23.4  12.8 16.4  26.3 
1 day 25.7  3.0 19.5  16.3 11.5  22.2 
2 days 7.1  1.0 14.8  17.7 6.2  48.2 
3 days 4.2  1.7 11.7  17.9 0.5  155.3 
4 days not detected  not detected not detected 
5 days not detected 3.1  47.4 not detected 
7 days not detected 0.7  165.1 not detected 
*Crushed tablet is Adalat® 10 mg retard (Bayer AG) 
aReported as mean-% SD of triplicate determinations for six samples. Initial nifedipine concentration per 
1.0 mg dose was 0.91 0.03 mg. 
bReported as mean-% SD of duplicate determinations for six samples.  
Initial nifedipine concentrations were c0.98 0.03 mg/ml and d1.03 0.04 mg/ml. 
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Figure 7. Chemical stability of nifedipine 1 mg oral powders stored at room temperature (24ºC) 
protected from light (—o—) and exposed to natural daylight at maximum 150 lux through the 
window in November in Finland (—x—) (preliminary study, unpublished data). The data is 
reported as mean-%±SD of triplicate determinations for six samples. An initial nifedipine dose 
was 0.92±0.03 mg. 
 
 
Figure 8. Spectrum of artificial full-colour daylight (300–800 nm) used in the photodegradation 
study (III). 
 
 
Figure 9. Spectrum of roomlight, which consists of natural daylight coming through a window 
and artificial light (300–800 nm) (III). 
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5.5 PHYSICAL STABILITY OF FORMULATIONS (II, III, V) 
At the end of the study intervals, the samples of drug-free hypromellose 1% solution and 
nifedipine suspensions (1 mg/ml) in 1% hypromellose vehicle protected from light were 
examined for any changes in their physical properties: pH, viscosity, density, osmolality 
and surface tension (II, III, V). The drug-free hypromellose 1% solution remained physically 
stable during the study period of 12 months at room temperature (Table 16) (II).  
The nifedipine unit-dose suspensions compounded either from tablets or drug powder 
also remained physically rather stable over 28 days either at room temperature or in a 
refrigerator protected from light and only minor changes in viscosity were detected (Tables 
17–18)(III). Suspensions made from crushed tablets were easier to redisperse than 
suspensions made from drug powder. Visual inspections revealed that no change in colour 
had occurred during the study period. The colour of the nifedipine suspensions changed 
when they were exposed to artificial daylight for 7 days. 
Sedimentation volumes of the unmixed nifedipine multi-dose suspensions during one 
month are illustrated in Figure 10 (V). No visible changes were observed in the suspensions 
made with Suspension Diluent A® and SyrSpend SF® Cherry vehicles. In all other 
suspensions, the presence of slight sediment was noticed. Suspensions compounded with 
Ora-Plus®/Ora-Sweet® and Hypromellose 1% had three distinct phases: a yellow solid 
powder sediment at the bottom of the flask, a yellow suspension phase in the middle of the 
suspension and a clear supernatant phase at the top (12 ml and 5 ml, respectively).  
Multidose suspensions behaved differently during resuspension after storage for 4 
weeks at room temperature (V). Suspension Diluent A®, Ora-Plus®/Ora-Sweet® and Ora-
Plus®/Ora-Sweet SF® could be readily dispersed into a uniform mixture. However, the 
SyrSpend SF® Cherry suspension could not be mixed properly as it remained stuck to the 
walls of the cylindrical graduated flask. The Methylcellulose 1%/Syrup NF and 
Hypromellose 1% suspension required 20–25 and 5–19 s of mixing, respectively, before they 
formed a uniform mixture. 
 
Table 16. Physical stability of drug-free hypromellose 1.0% solution during 12 months at room 
temperature (II). 
 
  Viscosity (mPa.s)    
Storage 
time 
pH Aa Bb Density 
(g/ml) 
Osmolalityb 
(mOsm/kg) 
Surface 
tensionb 
(mN/m) 
Before 
autoclaving 
6.81 7.1 8.8 1.0004 8 49 
After 
autoclaving 
6.80 6.9 8.4 1.0006 8 48 
3 months 6.77 7.4 8.6 0.9998 8 46 
6 months 6.79 6.9 8.0 1.0000 8 44 
12 months 6.94 7.6 7.5 1.0015 8 47 
A Haake Falling Sphere Viscosimeter 
B Haake Rotovisco RV2 
aReported as mean of five determinations 
bReported as mean of duplicate determinations 
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Table 17. Physical stability of nifedipine 1 mg/ml unit-dose suspension compounded with 
crushed tablets* (III). 
 
  Viscosity (mPa.s)    
Storage 
time (days) 
and 
temperature 
pH Aa Bb Density 
(g/ml) 
Osmolalityb 
(mOsm/kg) 
Surface 
tensionb 
(mN/m) 
Initial sample 7.00 16.0 10.6 1.0025 11 46 
14 (22°C) 7.00 13.0 not detected 1.0042 12 46 
14 (6°C) 7.02 13.0 not detected 1.0040 12 45 
28 (22°C) 6.95 10.8 8.2 1.0003 11 44 
28 (6°C) 6.94 12.0 8.2 1.0010 11 45 
*Crushed tablet is Adalat® 10 mg retard (Bayer AG) 
A Haake Falling Sphere Viscosimeter 
B Haake Rotovisco RV2 
aReported as mean of five determinations 
bReported as mean of duplicate determinations 
 
 
Table 18. Physical stability of nifedipine 1 mg/ml unit-dose suspension compounded with drug 
powder (III). 
 
  Viscosity (mPa.s)    
Storage 
time (days) 
and 
temperature 
pH Aa Bb Density 
(g/ml) 
Osmolalityb 
(mOsm/kg) 
Surface 
tensionb 
(mN/m) 
Initial sample 7.00 8.2 8.8 0.9987 10 49 
14 (22°C) 6.91 8.3 not detected 1.0016 9 47 
14 (6°C) 6.96 6.6 not detected 1.0011 8 47 
28 (22°C) 7.13 10.3 11.3 1.0015 9 43 
28 (6°C) 7.00 6.7 8.9 1.0002 8 46 
A Haake Falling Sphere Viscosimeter 
B Haake Rotovisco RV2 
aReported as mean of five determinations 
bReported as mean of two determinations 
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Figure 10. Sedimentation of the unmixed nifedipine 1 mg/ml multidose suspensions (20 ml) 
compounded with Suspension Diluent A® (left), Ora-Plus®/Ora-Sweet®, Ora-Plus®/Ora-Sweet 
SF®, SyrSpend SF® Cherry, Methylcellulose 1%/Syrup NF and Hypromellose 1% after one 
month storage at room temperature (unpublished data). 
 
5.6 MICROBIOLOGICAL STABILITY OF FORMULATIONS (II, III, V) 
No microbiological contamination was observed in any samples of drug-free hypromellose 
1% during a period of 6 months at room temperature (II). Because of probable laboratory 
contamination, Propionebacterium was found in one of the samples at 12 months, but the 
duplicate test was negative (sterile). 
The antimicrobial properties of nifedipine 1 mg/ml unit-dose suspension compounded 
with hypromellose 1% were examined (III). Freshly prepared nifedipine suspension did not 
inhibit the growth of microbes (Staphylococcus aureus, Bacteroides fragilis, Candida albicans). In 
the study of the microbiological stability of nifedipine suspension 1 mg/ml, no bacterial or 
fungal growth was observed in suspensions during the 28-day study period at room 
temperature or in a refrigerator (III).  
The microbiological quality of non-sterile nifedipine multidose suspensions was studied 
after four weeks of storage at room temperature (unpublished data) (V). Nifedipine 
suspensions compounded with Ora-Plus®/Ora-Sweet®, Ora-Plus®/Ora-Sweet SF®, 
Methylcellulose 1%/Syrup NF and Hypromellose 1% contained some microbial 
contamination (2–6 CFU/ml) but suspensions compounded with Suspension Diluent A® 
and SyrSpend SF® Cherry were free of microbes.  
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6 Discussion 
Although the tradition of compounding ‚lege artis‛ or ‚secundum artem‛ can be traced over a 
period of hundreds of years as a part of the professional skill of the pharmacist, the quality of 
the products being compounded has been inadequately studied. Many of the medicines used 
for neonates and children have not yet been licensed for this purpose and their use is 
considered off-label or unlicensed. This leads to a situation where attempts are made to modify 
an existing ‚adult‛ dosage form or an active ingredient and excipients are converted to an age-
appropriate paediatric formulation. The dose required for a child may be delivered in a portion 
of a tablet designed for adult. However; the range of doses and dosage forms is so variable that 
preparation for stock is not possible and extemporaneous preparation is essential. Thus, the 
background to this research project was to combine these two uncertainties and to choose and 
examine suitable oral dosage forms for paediatric formulations, which could be used in 
different ages of children and be modified for different situations likely to be encountered in the 
hospital setting.  
6.1 DOSAGE FORMS FOR PAEDIATRIC USE 
In many situations, oral liquids are the most suitable dosage forms for infants. However, in one 
pilot study it was noted that uncoated mini-tablets (2 mm in diameter) seemed to be a very 
promising alternative to liquid formulation even for infants aged 6-12 months (Spomer et al., 
2012). In the developing world, flexible solid dosage forms might be preferrable as the standard 
paediatric formulation to overcome the problems of cold storage, bulk trasportation and the 
availability of clean water to dissolve the formulations (Hoppu, Ranganathan and Dodoo, 2012). 
Thus, solid dosage forms such as oral powders, fast dissolving granules (sprinkles), granules, 
mini-tablets, orally disintegrating mini-tablets or dispersible dosage forms may be considered 
as alternatives to oral liquids (Salunke et al., 2011; Stoltenberg and Breitkreutz, 2011; Sam et al., 
2012).  
6.1.1 Capsules and oral powders 
Children still have medication needs that are not met by the commercially manufactured 
products. The present results demonstrate that compounded nifedipine capsules, which are 
emptied before use could safely replace oral powders in paediatric medication (IV). Capsules 
are faster to compound than powders due to the possibility for serial production by manually 
operated capsule filling devices instead of individual weighing. Both dosage forms are widely 
used in European hospitals (Brion, Nunn and Rietord, 2003). In addition, many children, even 
those aged 3 to 5 years, can comfortably swallow small sized capsules. 
Compounding of small capsules, such as size numbers 3 (0.30 ml) or 4 (0.21 ml), is acceptable 
when considering the recovered drug content, although the total weight of the oral powder 
should be 300 mg or more if one wishes to achieve the target content (IV, Figures 4–5). The loss 
of nifedipine during oral powder preparation and administration may be considerable, 
especially with powders, which have a relatively small mass, 100 mg or 50 mg. The surface area 
of capsule shell is smaller than the surface area of the powder paper, and this clearly reduces 
the loss of active ingredient. 
Capsules to be emptied and powders are suitable formulations for infants, since they can be 
easily added to milk, other liquid or to some pleasant-tasting semi-solid food to prevent 
aspiration of a powder and to mask the taste. Oral solids are simple to use at home, and the 
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stability of the drug is usually good. However, administration through a nasogastric tube 
requires a liquid form of drug. 
6.1.2 Unit-dose and multidose suspensions 
Special caution is needed in dispensing extemporaneously prepared oral suspensions in 
multidose containers since the variation between doses may be considerable (V). Incorrect 
dosages may be dispensed from poorly mixed suspension bottles. However, the quality of 
many commercial vehicles seems to be good when compared to compounded vehicles (V). The 
nifedipine doses in commercial vehicles were repeatable and accurate although the bottles were 
inverted only three times, which may be the situation in every day life.  
Sometimes there are recommendations issued to use extemporaneously prepared traditional 
Methylcellulose 1% suspension with Syrup NF in place of commercial Ora-Plus®/Ora-Sweet®. It 
was observed that the redispersion properties of Methylcellulose 1%/Syrup NF were 
significantly worse than those of Ora-Plus®/Ora-Sweet® (V, Tables 8 and 9). One explanation 
might be that the zeta potential of Methylcellulose 1%/Syrup NF was not optimized with 
excipients, such as electrolytes (Table 5). Here Methylcellulose 1% and Syrup NF were 
combined in the ratio 7:3 according to a traditional formula (Rappaport, 1983). According to 
USP, 1% to 2% methylcellulose dispersion can be mixed 1:1 with flavoured syrup to obtain a 
good suspension vehicle (The United States Pharmacopeial Convention, 2008). The quality of 
different ratios should be studied further. In addition, although compounded liquid 
formulations might be similar in terms of physicochemical properties, they might not be 
equivalent in vivo and thus not interchangeable (Salunke et al., 2011). Thus there is an evident 
need for standardised formulations and a universal suspending base. 
With pharmacy-prepared Hypromellose 1% as the suspension vehicle, it was not possible to 
formulate an ideal nifedipine multidose suspension but it was possible to produce a unit-dose 
suspension that met the requirements of dose accuracy, stability, microbiological quality and 
safety (II, III, V). In order to increase the physical stability of a multidose suspension, product 
development in the future should include the optimization of zeta potential using the required 
excipients (Table 5). In the Kuopio University Hospital, these kinds of preservative-free unit-
dose suspensions have been used successfully for many years and with many different 
medications. They have also been reported to be suitable for administering nimodipine 60 mg in 
unit-dose oral syringes for adult patients with acute subarachnoid haemorrhage (Soppi et al., 
2007). As long as aseptic preparation methods were employed, microbial contamination would 
seem to be only of minor concern. Before administration, only a small amount of air needs to be 
drawn into the syringe to readily resuspend any settled particles. The suspensions that were 
compounded in this study flowed easily through the small-bore nasogastric feeding tube, and 
no tube occlusions occurred.  
6.2 ORAL PAEDIATRIC NIFEDIPINE FORMULATIONS 
6.2.1 Nifedipine 
Licensed nifedipine products allow adults to benefit from once daily dosing, decreased risk of 
ADRs and formalised post-marketing surveillance (Standing and Tuleu, 2005). Children, who 
need to be treated with the same drug, have to take a dose three times a day, and are exposed to 
potentially increased risk of ADRs because no sustained release formulation is available. For 
medicines that may need to be used more than twice daily, there is a recommendation that the 
suitability of administration for children in the outpatient setting should be evaluated (European 
Medicines Agency EMA/CHMP/QWP/805880/2012 Rev. 2, 2013). Extended release nifedipine is 
administered for children initially 0.25–0.5 mg/kg/d with the dose divided 1–2 times/d, and then 
titrated to the desired effect (max 3 mg/kg/d up to 120 mg/d) (Meyers and Siu, 2011). The usual 
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recommendation in hypertension is to administer a modified release preparation to avoid large 
fluctuations in blood pressure (Standing and Tuleu, 2005). There are much more data 
supporting the use of the immediate-release formulation of nifedipine in acute hypertension 
(Meyers and Siu, 2011). 
In general, if one wishes to administer nifedipine orally to infants, one of the following 
methods has to be selected: 1) removal of nifedipine oily liquid from commercial soft capsules, 
2) splitting of nifedipine retard tablets into segments, crushing the segment and administering it 
with food or beverages, 3) importing commercial drops of nifedipine 20 mg/ml with special 
permission, or 4) preparation of extemporaneous suspensions, powders or capsules from 
crushed retard tablets or drug powder (Tuleu, Grange and Seurin, 2005; McCluskey and Brunn, 
2011).  
Unfortunately, different brands of nifedipine soft capsules contain different amounts of 
liquid and the volume of the content would need to be determined in order to make an accurate 
measurement (Rosen and Johnson, 1989; Tuleu, Grange and Seurin, 2005; McCluskey and 
Brunn, 2011). They contain polyethylene glycols as diluents and this might be harmful to 
infants. The required dose can be obtained for the use in infants by drawing the oily fluid from 
a 10 mg gelatin capsule into a syringe and administering the appropriate dose (Sahney, 2006; 
Seikaly, 2007). It is claimed that although short-acting nifedipine is a valuable drug for 
management of true hypertensive emergencies in children, it should be avoided in neonates 
because of the difficulty in accurately measuring the dose (Sahney, 2006).  
It is known that splitting of tablets leads to significant fluctuations in the administered 
nifedipine dose (Tuleu, Grange and Seurin, 2005). Nearly all the individual masses of 
segmented Adalat® retard 10 mg tablets deviated by more than 10% from the average weight. 
The time for 50% of the nifedipine to be released from crushed tablets of Adalat® retard was 10 
min, while for tablet halves it was 20 min and for whole tablets even longer, 25 min. The actual 
rate of dissolution in Adalat® retard tablets is controlled by the surface area of nifedipine 
crystals, but in vitro results have indicated that the tablets have only slightly extended release. 
Thus they may require three times daily dosing (BMJ Group, 2012). Real extended-release 
nifedipine tablets (such as Adalat® Oros 20 mg, Bayer on the market of Finland and Procardia© 
30, 60 and 90 mg, Pfizer on USA) cannot be broken up as this would distrupt the drug delivery 
system (Sahney, 2006; Seikaly, 2007; Meyers and Siu, 2011; Finnish Medicines Agency, 2013).  
In one published study, extemporaneous nifedipine 1 mg/ml suspension of a crushed 
Adalat® 10 mg retard –tablet and water produced doses ranging from 0.6 to 1 mg in the 1-ml 
syringes (Tuleu, Grange and Seurin, 2005). In unlicensed drops (Nifedipin-ratiopharm® Tropfen 
20 mg/ml, Ratiopharm) nifedipine is dissolved in macrogol 200, which may have potential 
toxicity issues in children. In such a concentrated liquid, a small variation in volume can 
produce a large error in the delivered dose: five drops contained from 5.7 to 5.9 mg nifedipine 
instead of 5 mg.  
Thus, extemporaneous suspensions, powders or capsules are the best option to produce 
nifedipine drug products for infants in hospitals. Although there has been progress in the 
treatment of paediatric hypertension, additional research is needed into the safety and efficacy 
of extemporaneous dosage formulations.  
6.2.2 Excipients 
The selection of the appropriate excipients for extemporaneous preparation is the responsibility 
of the pharmacist. It is clear the only essentials should be used in formulations intended for 
neonates. Solid drug formulations can mostly be composed using non-toxic excipients whereas 
toxicological risks are usually associated with excipients used in liquid formulations (Krause 
and Breitkreutz, 2008). 
The amount of preservatives should be kept at minimum and hypertonic solutions should 
not be used. Adverse toxic effects have been reported in paediatric patients due to the use of 
inappropriate excipients both in extemporaneous and commercial products. The properties of 
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the excipients may have also an influence on the uniformity of content and on loss of drug 
substance during its dispensing. The amounts of all excipients in manufactured medicines 
should also be listed on the label so that practitioners can consider their potential safety e.g. for 
children (Nahata, 2009). The amount of polysorbate in Adalat® 10 mg retard is only 1 mg, and it 
is thus below the WHO acceptable daily intake (25 mg/kg) also in a portion of a tablet (Napi, 
2013). 
The ingredients in the present nifedipine oral powder and capsule studies were selected 
because of their flow properties and particle size distribution (I, IV). Both lactose and 
microcrystalline cellulose are widely used and safe excipients in solid oral pharmaceutical 
formulations. Due to intestinal immaturity, preterm infants have diminished levels of the 
lactase enzyme, which hydrolyses lactose, but it has been reported that expression of this 
enzyme can be induced by lactose ingestion (Guandalini et al., 2012). Symptoms of lactose 
intolerance rarely develop in children younger than 6 years. Lactose is also contraindicated in 
infants with galactosemia, a rare congenital disorder (Pawar and Kumar, 2002). There was some 
discussion in the 1970’s about the persorption of microcrystalline cellulose after its per oral 
administration (Pahlke and Friedrich, 1974 and 1975; Seidemann, 1976).  
The excipients to be used in the suspension formulation for neonates and infants have to be 
selected carefully (II, III, V). There are some recommendations and limits for use, and the dose-
response relationship has to be considered. Commercial vehicles may contain excipients, which 
may cause concern. In the UK, the Food Advisory Committee has recommended that 
carrageenan should not be used as suspending agent in infant formulas (Rowe, et al., 2012). 
WHO has set an estimated total acceptable daily intake of 10 mg/kg for parabens and 2.5 mg/kg 
for saccharin sodium (Pawar and Kumar, 2002). Saccharin is approved for children over three 
years old (Pawar and Kumar, 2002; Costello, 2007; Rowe et al., 2012). Sodium benzoate can 
produce nonimmunological contact urticaria and non-immunological immediate contact 
reactions (Rowe et al., 2012). If one reviews these vehicles, then parabens is present in 
Suspension Diluent A®, Ora-Sweet®, Ora-Plus® and Ora Sweet SF®, and in addition, Ora-Sweet 
SF® contains saccharin and Ora-Plus® contains carrageenan (V). Sodium benzoate is used in 
SyrSpend SF® Cherry and in Methylcellulose 1%.  
In addition, high osmolality vehicles are inadvisable for neonates and infants. Hypertonic 
solutions, over 400 mOsm/kg, may cause injury to the GI tract of neonates (Polo et al., 2007, de 
Villiers, 2009b). Ora-Sweet®, Ora-Sweet SF® and Methylcellulose 1%/Syrup NF are 
hyperosmolar vehicles: 3240 mOsm/kg, 2150 mOsm/kg and 1125 mOsm/kg, respectively (V). 
Instead, the osmolalities of Suspension Diluent A®, Ora-Plus®, SyrSpend SF® Cherry and 
Hypromellose 1% are low: 17 mOsm/kg, 230 mOsm/kg, <50 mOsm/kg and 8 mOsm/kg, 
respectively. 
Preservative-free cellulose gels like hypromellose are believed to be safe and suitable for 
neonatal use and easy to administer through a nasogastric tube (III). Hypromellose E50 has also 
been used as a vehicle for hydrochlorothiazide 2 mg/ml suspensions at a concentration of 1.5% 
(Tötterman et al., 1994). Unfortunately customized amounts of hypromellose 50 mPa.s cannot be 
purchased nowadays and this will restrict its use in the future. 
The pharmacist must consider the system’s capability to resist microbial growth. It has been 
reported that Methylcellulose 1%/Syrup NF dilutions in ratios greater than 1:1 have failed the 
European Pharmacopoeia quality assurance criteria for efficacy of antimicrobial preservation 
(Ghulam et al., 2007). Sodium benzoate, which was used as preservative in this formulation, is 
effective only at pH 5.0 or lower, while the pH of the vehicle was 6.6 (de Villiers, 2009a). 
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6.3 UNIFORMITY OF DOSAGE UNITS 
The uniformity of dosage units is a major factor if one wishes to assure the repeatability of 
dosages and thus, the dispensing of a safe and effective medication. Although uniformity 
testing is a requirement of European Pharmacopoeia and USP Pharmacists’ Pharmacopeia, 
actual results can seldom be found in peer-reviewed journals. In addition, the test is not a 
pharmacopoeial requirement for multidose suspensions (European Directorate for the Quality 
of Medicines & Health Care, 2013). 
6.3.1 Critical steps in compounding process 
Hand crafted procedures are widely used in hospital and community pharmacies. Crushing of 
tablets is the critical point in the powder mass preparation. The importance of the crushing 
technique becomes emphasized in small size oral powders, where more variation in content can 
be observed. Manual tablet crushers are mostly used, and in fact, here electrical crushers were 
not found to be very practical. Commercial tablets have a specific content uniformity variation 
of their own, which may lead to some variation in the modified dosage forms.  
The grinding time and technique can influence the resulting homogeneity of the powder 
mixture by affecting the electrostatic properties of the powder. Mixing the powder mass with a 
mortar and pestle may introduce a variable in the procedure. It also has to be noted that 
particles may become segregated if they need to be stored before dispensing. The particle size of 
the crushed nifedipine tablet, which was less than 100 μm, was about the same size as the 
excipients and in this way it was possible to prevent stratification between large and small 
particles (II). 
6.3.2 Redispersion of suspension 
A suspension should dispense drug particles uniformly after brief shaking of the bottle, so that 
the desired dose can be measured accurately (Nahata, 1999d). In practise, the compounding 
pharmacist does not have the possibilities of the industrial formulator to control flocculation 
with electrolytes, polymers and surfactants. Thus the best choice is to use polymers or 
protective colloids to increase the viscosity and to provide a mechanical barrier by coating the 
individual particles.  
The significance of the zeta potential on the physical stability of a suspension is well-known 
(Sinko and Singh, 2011). It is apparent that crushing of tablets may produce charged particles. 
The desired zeta potential may be acvieved by the addition of excipients, such as electrolytes 
and/or buffering agents including sodium phosphate and sodium citrate as in Ora-Sweet®, Ora-
Sweet SF®, Ora-Plus® or SyrSpend SF® Cherry (Table 5). Xanthan gum included in Suspension 
Diluent A®, as itself, is an anionic material (Rowe et al., 2012). Wetting properties may be 
improved by surfactants such as those present in Ora-Plus® and SyrSpend SF® Cherry. Viscosity 
increasing agents were used in all of the suspension vehicles in the present study to retard the 
settling of dispersed particles.  
After 1 week of storage at room temperature, the nifedipine multi-dose suspension prepared 
with Methylcellulose 1%/Syrup NF failed to provide more than 70% of its intended dose if it 
was shaken only three times (V, Table 9). Since the doses drawn from the bottle were similar 
and the standard deviation was small, the most likely explanation is that there had been cake 
formation in the suspension. The nifedipine-Hypromellose 1% suspension lost less than 30% of 
the dose in one-week storage and the doses were variable but this might be a consequence of 
the inadequate mixing (V, Table 10). The compact sediment at the bottom of the multi-dose 
container in nifedipine suspensions compounded with Methylcellulose 1%/Syrup NF or 
Hypromellose 1% required prolonged shaking before it could be reconstituted into a uniform 
suspension.  
Suspensions should always be shaken well before use to ensure uniform distribution of the 
solid in the vehicle (The United States Pharmacopeial Convention, 2008). However the 
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command ‚Shake well before using‚ may be understood in different ways in the pharmacy, on 
the ward and particularly at home. Many dosing errors may occur because patients do not 
observe handling intructions (Deicke and Süverkrüp, 2000). Pharmacopoeias require that 
suspensions should be redispersible but none of them provides specifications about how this 
can be verified experimentally. Thus, pharmacopoeial monographs on oral liquids should 
include a standardized procedure for testing the redispersibility of suspensions.  
Mixing techniques of suspensions are important if one wishes to obtain the required amount 
of liquid. In published stability studies, suspensions are usually mixed very well and properly 
to achieve a good sample: for example shaken for about ten to 30 seconds or vortexed for 60 
seconds or shaken on a wrist-action shaker for 10 minutes, then allowed to stand for 2 minutes 
and gently inverted three times (Nahata and Morosco, 2003a, 2003b and 2004; Nahata, Morosco 
and Brady, 2006; Trissel, Zhang and Koontz, 2006; Winiarski et al., 2007; Aliabadi et al., 2011). 
Proper mixing is important for homogenous samples but these tests do not reveal the possible 
mixing problems in daily life. Thus the results of these studies may not reflect the actual use of 
the suspension. 
6.4 CHEMICAL STABILITY OF NIFEDIPINE 
Compounded nifedipine powders, capsules and suspensions provided adequately stability for 
storage and use in hospitalised patients (I, III–V). Since the preparations were stable in the 
secondary package but unstable if not properly stored, it was necessary to label products clearly 
to prevent storage without secondary package. The photodegradation of nifedipine was faster 
in suspensions made from drug powder than in those made from tablets because of light-
protective effect of the excipients present in the tablets (III). The analytical results of powder 
papers, capsules and unit-dose syringes tend to display greater variations because these are 
distinct dosage units rather than aliquots of drugs in solution (I–IV).  
Nifedipine crystals are more stable than nifedipine solutions because the effect of light is a 
surface phenomenon (Thoma and Klimek, 1985b). Nifedipine solution in methanol underwent 
more than 10% photodegradation in approximately 5–10 minutes (Grundy, Kherani and Foster, 
1994). On exposure to daylight in winter, 10% of nifedipine in solution was degraded in about 7 
minutes and in summer 10% degradation only required about 1 minute (Thoma and Klimek, 
1985a). The degradation of nifedipine in solutions occurs three-fold faster in normal daylight 
than under exposure to a 40 W light bulb (Thoma and Klimek, 1991a).  
Tuleu, Grange and Seurin (2005) found that crushed nifedipine tablet in an extemporaneous 
water suspension (1 mg/ml) started to degrade after 15 min of exposure to light, and 7% had 
degraded in 30 min and 11% had disappeared within 60 min when stored on the bench not 
protected from light. Nahata, Morosco and Willhite (2002) investigated the stability of 
nifedipine in two oral suspensions and found them to be stable for up to three months in 
refrigerator and at room temperature if they were stored in amber plastic bottles. Nifedipine 
was taken from punctured liquid-filled capsule and vehicles were Methylcellulose 1%/Syrup 
NF (1:13) and Ora-Plus®/Ora-Sweet® (1:1). Both suspensions were shaken for 10 minutes before 
sampling. 
Dentinger, Swenson and Anaizi (2003) found that extemporaneously prepared nifedipine 10 
mg/ml oral solution packaged in amber glass bottles or amber oral syringes wrapped in 
aluminium foil retained more than 90% of the initial concentration for 35 and 14 days, 
respectively, at 22–25°C when exposed to fluorescent light. Instead, samples stored in amber 
syringes but not wrapped in foil had lost over 20% of the initial nifedipine concentration within 
7 days. The nifedipine solution in that study was prepared from nifedipine powder with 
polyethylene glycol 400, glycerol, and peppermint oil. In a stability study of a nifedipine 
cardioplegic solution, it was noted that even when protected from light with a brown plastic 
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wrapper and refrigerated, nifedipine concentrations decreased to less than 90% of original 
potency within approximately six hours (Bottorff et al., 1984). 
A decrease of 20% in nifedipine content has been observed to occur after 18 hours when a 
pulverized tablet in a sealed paper was stored under normal laboratory light, i.e. a mixture of 
daylight and fluorescent light (700 lux) (Ohkubo, Noroi and Sugawara, 1992). In another study 
there was more than 10% photodegradation of nifedipine in powder within 24 hours of artificial 
sunlight exposure (Grundy, Kherani and Foster, 1994). Solid nifedipine showed complete 100% 
photodecomposition within 6 hours when exposed to sunlight (Sadana and Ghogare, 1991). 
Gold-shaded fluorescent lighting (over 525 nm) appeared to prevent nifedipine degradation 
during compounding (McCluskey and Brunn, 2011). Thus, nifedipine must be protected from 
light very carefully during compounding and storage (Thoma and Klimek, 1991b). 
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7 Conclusions 
According to these studies, the following conclusions can be drawn: 
 
The individual needs of each child can be satisfied with age-appropriate nifedipine oral 
dosage forms. In these studies, nifedipine 1 mg/dose was compounded into capsules, powders 
or single-dose and multidose suspensions. 
 
1. Capsules, whose contents are emptied prior to use, provide an alternative to oral 
powders for preparing paediatric oral solid medications. The content uniformities 
capsules and oral powders met the established requirements. However, the nifedipine 
amount was less than 80% of the theoretical value in oral powders of total weights 
either 100 mg or 50 mg. 
2. Nifedipine oral powders were chemically stable for up to one year when stored at 
room temperature or in refrigerator as long as they were protected from light.  
3. A 1.0% hypromellose solution displayed the best properties as a suspending agent for 
unit-dose suspensions. Steam sterilized preservative-free hypromellose 1.0% solutions 
were microbiologically satisfactory and could be kept at room temperature for at least 
6 months.  
4. Nifedipine unit-dose suspensions were chemically, physically and microbiologically 
stable throughout the 4-week study period when stored at room temperature or in a 
refrigerator protected from light. The content uniformity of the unit-dose suspensions 
met the established requirements.  
5. When exposed to artificial daylight, nifedipine in either powder or suspension 
degraded rapidly at room temperature. Overall, 20–30% photodegradation of the 
nifedipine occurred within three hours. 
6. Multi-dose suspensions compounded with Methylcellulose 1%/Syrup NF or 
Hypromellose 1% require mixing by inverting the bottle 10–15 times to comply with 
the content uniformity test. In contrast, the commercial suspension vehicles passed the 
test if the bottle was inverted only three times. 
 
The art of compounding has a long tradition; however, there have been few scientific 
investigations into this area. These results offer practical tools for the assessment and resolving 
the daily challenges encountered in compounding of paediatric oral formulations in 
pharmacies. 
In further studies it would be worthwhile to determine whether nifedipine doses under 1 mg 
fulfil the requirements of content uniformity. In addition, extemporaneous suspension vehicles 
should be further examined. 
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formulations is a worldwide 
problem. This study investigated the 
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unit-dose or multi-dose suspensions 
are sufficiently uniform and stable?
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